

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



B11

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C07K 1/00, 3/08</b>		<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 94/01451</b> <b>(43) International Publication Date:</b> 20 January 1994 (20.01.94)
<b>(21) International Application Number:</b> PCT/US93/06591 <b>(22) International Filing Date:</b> 13 July 1993 (13.07.93) <b>(30) Priority data:</b> 07/912,798                      13 July 1992 (13.07.92)                      US <b>(71) Applicant:</b> BIONEBRASKA, INC. [US/US]; 3940 Cornhusker Highway, Suite 600, Lincoln, NE 68504 (US). <b>(72) Inventors:</b> STOUT, Jay ; 1921 Sewell, Lincoln, NE 68502 (US). WAGNER, Fred, W. ; Route 1, Box 77B, Walton, NE 68461 (US). COOLIDGE, Thomas, R. ; Beebe Hill Road, Falls Village, CT 06031 (US). HOLMQUIST, Bart ; 335 Prospect Hill Road, Waltham, CT 02154 (US).			<b>(74) Agent:</b> BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Welter & Schmidt, 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402 (US). <b>(81) Designated States:</b> AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> METHOD FOR MODIFICATION OF RECOMBINANT POLYPEPTIDES			
<b>(57) Abstract</b>  The invention provides for a chemical method for preparing a recombinant single copy polypeptide or a portion thereof with a modified terminal amino acid $\alpha$ -carbon reactive group selected from the group consisting of N-terminal $\alpha$ -amine, C-terminal $\alpha$ -carboxyl, and a combination thereof. The steps of the method involve forming the recombinant single copy polypeptide or a portion thereof so that the single copy polypeptide is protected with one or more biologically added protecting groups at the N-terminal $\alpha$ -amine, C-terminal $\alpha$ -carboxyl. The recombinant single copy polypeptide can then be reacted with up to three chemical protecting agents to selectively protect reactive side chain groups and thereby prevent side chain groups from being modified. The recombinant single copy polypeptide can be cleaved with at least one cleavage reagent specific for the biological protecting group to form an unprotected terminal amino acid $\alpha$ -carbon reactive group. The unprotected terminal amino acid $\alpha$ -carbon reactive group is modified with at least one chemical modifying agent. The side chain protected terminally modified single copy polypeptide is then deprotected at the side chain groups to form a terminally modified recombinant single copy polypeptide. The number and sequence of steps in the method can be varied to achieve selective modification at the N- and/or C-terminal amino acid of a recombinantly produced polypeptide.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

1

METHOD FOR MODIFICATION OF  
RECOMBINANT POLYPEPTIDES

5

Background of the Invention

Many naturally occurring proteins and peptides have been produced by recombinant DNA techniques. Recombinant DNA techniques have made possible the selection, amplification and manipulation of expression of the proteins and peptides. For example, changes in the sequence of the recombinantly produced proteins or peptides can be accomplished by altering the DNA sequence by techniques like site-directed or deletion mutagenesis.

However, some modifications to a recombinantly produced protein or peptide can not be accomplished by altering the DNA sequence. For example, the C-terminal  $\alpha$ -carboxyl group in many naturally occurring protein and peptides often exists as an amide, but this amide typically is not produced through recombinant expressing and is biologically converted after expression in vivo from a precursor protein to the amide. Another example is the addition of a D-amino acid to the N- and/or C-terminal end of a recombinantly produced protein or peptide.

In addition, it may be desirable to selectively modify both the N- and C-terminal  $\alpha$ -carbon reactive groups of a recombinantly produced protein or peptide. Recombinantly produced protein or polypeptides have a multiplicity of reactive side chain groups, as well as the N- and C-terminal amino acid  $\alpha$ -carbon reactive groups. Side chain reactive groups include thiols, carboxyls, imidazoles, and  $\epsilon$ -amine reactive groups. Selective modifications at the N- and/or C-terminal  $\alpha$ -carbon reactive groups, such as adding an N-terminal pyroglutamyl residue and/or forming an amide at the C-terminal amino acid, need to be conducted without adversely affecting the reactive side chain groups.

A method of forming a C-terminal amide on a recombinantly produced polypeptide by the action of an enzyme is known. The enzyme is peptidyl glycine  $\alpha$ -amidating monooxygenase and is present in eukaryotic systems. The enzyme has been used to form an amide on the C-terminal amino acid of recombinantly produced peptides, like human growth hormone releasing hormone in vitro as described by J. Engels, Protein Engineering, 1:195-199 (1987).

- 10 In addition many recombinantly produced small proteins and peptides have a limited number of reactive side chain groups. For example, the 27 amino acid human gastrin releasing peptide contains N-terminal  $\alpha$ -amine and side chain hydroxyl and  $\epsilon$ -amine reactive groups.
- 15 The myosin light chain kinase inhibitor contains 10 amino acids and has N-terminal  $\alpha$ -amine and side chain  $\epsilon$ -amine reactive groups. The C-terminal  $\alpha$ -carboxyl groups are amidated in both of these naturally occurring peptides. Although these types of small proteins and
- 20 peptides have a limited number of different reactive groups, they have been amidated through the traditional method of enzymatic C-terminal amidation. While selective, the enzymatic method is time consuming, expensive, gives unpredictable yields, and requires
- 25 significant post reaction purification. The enzymatic method is also limited to modifying the recombinantly produced peptide by C-terminal amidation.

Accordingly, there is a need for a chemical method that provides for selective modification of either or both N-terminal  $\alpha$ -amine and C-terminal  $\alpha$ -carboxyl groups of a recombinantly produced polypeptide. This method results in selective modifications to one or both terminal amino acid  $\alpha$ -carbon reactive groups and does not adversely affect

35 the reactive side chain groups. There is also a need for a method of selective modification that allows addition of a variety of different organic moieties to

the N- and/or C-terminal  $\alpha$ -carbon reactive groups of a recombinantly produced polypeptide and that is convenient, cheap and capable of producing terminally modified recombinant polypeptides in high yield.

- 5 Therefore, it is an object of the invention to develop a chemical method for selective modification of N-terminal  $\alpha$ -amine and/or C-terminal  $\alpha$ -carboxyl reactive groups of a recombinantly produced polypeptide.

10

#### Summary of the Invention

- These and other objects are accomplished by the present invention. The invention provides for a chemical method for preparing a recombinant single copy polypeptide or portion thereof with a modified terminal
- 15 amino acid  $\alpha$ -carbon reactive group selected from the group consisting of an N-terminal  $\alpha$ -amine, C-terminal  $\alpha$ -carboxyl and a combination thereof. The recombinant single copy polypeptide also has reactive side chain groups selected from the group consisting of an  $\epsilon$ -amine
- 20 group, a hydroxyl group, a  $\beta$ -carboxyl group, a  $\gamma$ -carboxyl, a thiol group, and a combination thereof.

- The steps of the method involve forming the recombinant single copy polypeptide or a portion thereof so that the single copy polypeptide is protected with
- 25 one or more biologically added protecting groups at the N-terminal  $\alpha$ -amine and/or the C-terminal  $\alpha$ -carboxyl. The recombinant single copy polypeptide is then reacted with up to three chemical protecting agents to
- 30 selectively protect reactive side chain groups to form a side chain protected recombinant single copy polypeptide and thereby prevent the side chain group from being modified during the modification reaction. The
- recombinant single copy polypeptide is cleaved with at least one cleavage reagent specific for the biologically
- 35 added protecting group to form a recombinant polypeptide with unprotected terminal amino acid  $\alpha$ -carbon reactive group. Alternatively, the single copy polypeptide can

be cleaved with at least one cleavage reagent specific for the biological protecting group followed by reaction with up to three chemical protecting agents. In either case, a side chain protected single copy polypeptide having an unprotected terminal amino acid  $\alpha$ -carbon reactive group is produced. The unprotected terminal amino acid  $\alpha$ -carbon reactive group is then modified with at least one chemical modifying agent. The resulting side chain protected terminally modified single copy polypeptide is then deprotected at the side chain groups to form a terminally modified recombinant single copy polypeptide.

The recombinant single copy polypeptide or portion thereof is formed with one or more biologically added protecting group on the terminal amino acid  $\alpha$ -carbon reactive groups. The biologically added protecting group can be a peptide, a polypeptide, amino acid, or a combination thereof connected to the N- and/or C-terminal  $\alpha$ -carbon reactive groups by an amide bond connection. The biological protecting group bond is stable and generally irreversible and, thus, contains at least one recognition sequence that is cleavable enzymatically or chemically. The recombinant polypeptide with one or more biologically added protecting groups is formed by incorporating the DNA sequence for the biologically added protecting group or groups into the expression cassettes adjacent to the sequence for the recombinantly produced protein or peptide.

For example, the recombinant single copy polypeptide can be formed as a single copy fusion protein. The single copy fusion protein has a binding protein connected via an interconnecting peptide to the single copy polypeptide at either the N- and/or C-terminal  $\alpha$ -carbon reactive group. The interconnecting peptide has at least one site that is cleavable by a chemical or enzymatic reagent and serves as a biological

protecting group. The binding protein and interconnecting peptide not only serve as a biological protecting group, but also aid in purification of the recombinant single copy polypeptide. For example, a  
5 single copy fusion protein having a binding protein of carbonic anhydrase and a polypeptide of any peptide sequence can be purified through use of an immobilized reversible inhibitor such as benzene sulfonamide. Further, the carbonic anhydrase can be modified to  
10 eliminate cleavage sites which would also be cleaved along with cleavage of the interconnecting peptide. In a preferred embodiment, two cleavage sites can be incorporated within the interconnecting peptide so that after purification of the fusion protein, the binding  
15 protein can be cleaved to leave a short peptide sequence (e.g., the interconnecting peptide) as the biological protecting group for the single copy polypeptide. This demifusion protein can be modified according to the invention to protect its reactive side chain groups.  
20 The short peptide sequence residue acts as the biological protecting group of the N-terminal  $\alpha$ -amine of the demifusion protein. Enzymatic or chemical cleavage of this short peptide sequence releases the free N-terminal  $\alpha$ -amine for further modification according to  
25 the invention.

The recombinant single copy polypeptide can also be formed having only a portion of the amino acid sequence of the desired polypeptide or as a truncated version of the polypeptide. Preferably, the portion of  
30 the sequence is lacking from about 1 to about 10 of the terminal amino acids of the polypeptide. The portion of the recombinant single copy polypeptide is formed so that it is biologically protected at the N- and/or C-terminal end with a polypeptide, peptide, or amino  
35 acid as described above. The portion of or truncated version of the single copy polypeptide can also be formed as a multicopy polypeptide or fusion protein.

The starting material of the invention can also be recombinantly formed as a multicopy polypeptide or fusion protein. The multicopy polypeptide has several copies of the single copy polypeptide tandemly linked

5 together with or without an intraconnecting peptide. If an intraconnecting peptide is present, it has at least one site that is selectively cleavable by a chemical or enzymatic cleavage reagent. The intraconnecting peptide also acts as a biological protecting group at the

10 C-terminal portion of one or more single copy polypeptides incorporated into the multicopy polypeptide. A multicopy fusion protein has three tandemly linked segments including a binding protein connected via an interconnecting peptide to the

15 multicopy polypeptide. The interconnecting peptide has at least one site that is selectively cleavable by a chemical or enzymatic method and is preferably different from the intraconnecting peptide. The binding protein with interconnecting peptide acts as a biological

20 protecting group and aids in the purification of the recombination multicopy polypeptide. In a preferred multicopy embodiment like the embodiment described above for the single copy fusion protein, the multicopy polypeptide can have as a binding protein carbonic

25 anhydrase. The carbonic anhydrase can be modified so that it does not contain cleavage sites which are to be used in both the interconnecting peptide and the intraconnecting peptide. The interconnecting peptide preferably contains at least two cleavage sites. After

30 separation and purification through use of the binding protein, the binding protein fragment is removed by cleavage at a unique cleavage site within the interconnecting polypeptide. Separation of the binding protein fragment from the multicopy polypeptide and side

35 chain protection according to the invention produces a protected multicopy polypeptide ready for cleavage into single copies and release of the free N-terminal  $\alpha$ -

amine. Selection and addition of the appropriate enzyme, enzymes or chemicals for cleavage of the biological protecting group and/or the intraconnecting peptides releases the free  $\alpha$ -amine or free  $\alpha$ -carboxyl group of the several copies of the desired polypeptide. The protected polypeptide can then be modified at the N-terminal or C-terminal or both as desired.

The starting materials of the invention are selected and recombinantly produced with biologically added protecting groups. The starting materials can include a biologically protected recombinant single copy polypeptide or portion thereof, a recombinant single copy fusion protein, a recombinant multicopy fusion protein, and a biologically protected recombinant multicopy polypeptide. The preferred starting material is a recombinant single or multicopy fusion protein.

Once the starting material of the invention is selected and formed, the starting material is treated to produce a protected single copy polypeptide having an unprotected terminal amino acid  $\alpha$ -carbon reactive group. The starting material is reacted with up to three chemical protecting agents to form a side chain protected molecule to prevent reaction of side chain reactive groups with the modification agent. The starting material is cleaved with a cleavage reagent specific for the biologically added protecting group to form an unprotected terminal amino acid  $\alpha$ -carbon reactive group. The number and sequence of steps of cleaving and reacting the starting material with up to three chemical protecting agents can vary depending on several factors, including:

- (a) if the starting material of the invention is a multicopy polypeptide or fusion protein, extra cleavage steps can be required;
- (b) if the modification desired is at the N- and/or C-terminal  $\alpha$ -carbon reactive group, extra cleavage and modification steps are required;

(c) the amino acid sequence of the desired polypeptide, the number of side chain reactive groups, and whether a cleavage recognition sequence is present will influence whether the polypeptide is protected

5 first or cleaved first; and

(d) the type of modification - for example, some types of modification reactions do not require protection of side chain reactive groups.

The number and sequence of cleaving and  
10 reacting steps are selected to achieve a protected single copy polypeptide having an unprotected terminal  $\alpha$ -carbon reactive group. For example, a recombinant multicopy fusion protein can be terminally modified as follows. The recombinant multicopy fusion protein is  
15 recombinantly formed having a binding protein connected to an interconnecting peptide which is connected to the N- or C-terminal end of the multicopy polypeptide. The multicopy polypeptide has several copies of the single copy polypeptide connected with intraconnecting  
20 peptides. The interconnecting peptide and intraconnecting peptide act as biological protecting groups and each have at least one chemical or enzymatic cleavage site. The multicopy fusion protein is first cleaved with cleavage reagents specific for the  
25 interconnecting peptide to form a multicopy polypeptide. The multicopy polypeptide is then reacted with up to three chemical protecting agents to protect reactive side chain groups followed by cleavage with at least one cleavage reagent specific for the biologically added  
30 protecting group or in the reverse order. The cleavage reagent specific for the biologically added protecting groups act to cleave at the intraconnecting peptide and to remove remaining intraconnecting peptide residues. In either case, a protected single copy polypeptide  
35 having an unprotected terminal amino acid  $\alpha$ -carbon reactive group is produced. The terminal  $\alpha$ -carbon reactive group is modified. The terminally modified

single copy polypeptide is deprotected to yield a terminally modified recombinant single copy polypeptide.

The unprotected terminal  $\alpha$ -carbon reactive groups can be modified by reaction with a chemical modifying agent. The modifying agent acts to add or replace terminal amino acids with organic moieties. Specific examples of types of modifications include: C-terminal amidation; addition or replacement of terminal amino acids with a D-amino acid, an L-amino acid, an amino acid derivative, or peptides having a combination thereof; formation of an N-acetyl group; formation of an N-terminal amide or other N-terminal addition moiety through reaction of an unprotected  $\alpha$ -amine group with a chemically produced oligopeptide or a synthetic organic moiety having a reactive group which will form a covalent bond with the N-terminal  $\alpha$ -amine. Modification can occur at one or both terminal  $\alpha$ -carbon reactive groups.

Once a protected recombinant single copy polypeptide is modified, it is deprotected under conditions allowing regeneration of the original side chain reactive groups. The final product is a terminally modified recombinantly produced single copy polypeptide. Modifications can change the biological activity or structure of the desired recombinant polypeptide.

#### Detailed Description of the Invention

Recombinant DNA techniques have made possible the selection, amplification, and manipulation of expression of many naturally occurring proteins and peptides. Naturally occurring proteins and peptides recombinantly produced generally contain a multiplicity of amino acids having side chains with different functional or reactive groups including hydroxyl, thiols, carboxyls, and  $\epsilon$ -amine groups. Two other important reactive groups are the N-terminal  $\alpha$ -amine

reactive group and the C-terminal  $\alpha$ -carboxyl reactive group. It is often desirable to selectively modify a recombinant polypeptide at the N-terminal  $\alpha$ -amine and/or C-terminal  $\alpha$ -carboxyl groups. For example, the

5 C-terminal reactive carboxyl groups in some naturally occurring proteins and peptides can be selectively converted to an amide to provide for enhancement of biological activity. Alternatively, a D-amino acid or peptide could be added to or replace a terminal amino

10 acid.

These modifications can result in the formation of analogs of the recombinantly produced polypeptide that are longer acting and more potent than the naturally occurring polypeptide. Generally, these types

15 of modifications to the recombinantly produced polypeptide are not accomplished by alteration of the DNA sequence for the recombinantly produced polypeptide because there is no genetic code providing for amino acid amides, or incorporation of D-amino acid or an

20 amino acid derivative.

The present invention provides a method for the selective modification of a recombinantly produced polypeptide at a terminal  $\alpha$ -carbon reactive group selected from the group consisting of N-terminal

25  $\alpha$ -amine, C-terminal  $\alpha$ -carboxyl and a combination thereof. The first step in the method is to form the recombinantly produced single or multicopy polypeptide so that it is protected at one or both terminal  $\alpha$ -carbon reactive groups with a biologically added protecting

30 group.

The biologically added protecting group is preferably an amino acid, peptide, and/or polypeptide that contains at least one site that is cleavable enzymatically or chemically, and preferably has a


35 sequence that is not present in the sequence of the desired polypeptide. The biologically added protecting group can be added to the recombinantly produced

- polypeptide by combining the DNA sequence for the biologically added protecting group to the 5' and/or 3' terminus of the gene encoding the desired polypeptide. Once formed, the recombinantly produced polypeptide,
- 5 biologically protected at the terminal  $\alpha$ -carbon reactive groups, is reacted with up to three chemical protecting agents to protect the side chain groups and then is cleaved with at least one cleavage reagent specific for at least one biologically added protecting group.
- 10 Alternatively, the recombinant single copy polypeptide, biologically protected at the terminal  $\alpha$ -carbon reactive group, is cleaved with a cleavage reagent specific for at least one biologically added protecting group and then reacted with up to three chemical protecting agents
- 15 that act to protect side chain reactive groups. In either case, a polypeptide is produced having an unprotected N- or C-terminal  $\alpha$ -carbon reactive group and protected side chain reactive groups. The unprotected terminal amino acid  $\alpha$ -carbon reactive group is modified
- 20 with a modifying agent to form a terminally modified protected single copy polypeptide. The terminally protected single copy polypeptide is then deprotected to form an N- and/or C-terminally modified single copy polypeptide.
- 25 The sequence and number of steps in the method of the invention can be varied depending on the desired modification, the amino acid sequence of the desired polypeptide, and the starting material selected. The starting materials of the invention can include a
- 30 recombinantly produced single copy polypeptide, or a portion thereof, a multicopy polypeptide, a single copy fusion protein, and a multicopy fusion protein.
- For example, the method of the invention provides for the selective N-terminal  $\alpha$ -amine and
- 35 C-terminal  $\alpha$ -carboxyl modification of a recombinantly produced single copy polypeptide. A recombinantly produced single copy polypeptide is formed so that the

N-terminal  $\alpha$ -amine is biologically protected by an amide bond connection to an interconnecting peptide and optionally a binding protein and the C-terminal  $\alpha$ -carboxyl is biologically protected by an amide bond connection to an arginine residue. The recombinant single copy polypeptide biologically protected at both the N- and C-terminal  $\alpha$ -carbon reactive groups is then reacted with up to three chemical protecting agents so that the reactive side chain groups present in the recombinant single copy polypeptide are protected and not available to react with the modifying agent. The protected single copy polypeptide is then cleaved with a cleavage reagent specific for the N-terminal biological protecting group and the unprotected  $\alpha$ -amine group is reacted with a chemical modifying reagent. The modified side chain protected single copy polypeptide is then cleaved with a cleavage reagent specific for the C-terminal biological protecting group. The unprotected C-terminal  $\alpha$ -carboxyl group is reacted with a second modifying agent to form a side chain protected N-terminal modified, C-terminal modified single copy polypeptide. The protected N-terminal, C-terminal modified single copy polypeptide is deprotected at the side chain reactive groups to form a recombinant single copy polypeptide modified at the N- and C-terminal ends of the molecule. The reaction scheme showing sequential N-terminal  $\alpha$ -amine and C-terminal  $\alpha$ -carboxyl modification of a recombinant single copy polypeptide is as follows:

### Reaction Scheme I:

## Selective Modification at the N- and C-Terminal Amino Acid of a Recombinant Single Copy Polypeptide



**Key**

50 BPI<sub>1</sub> - scPP - Arg = recombinant single copy fusion  
protein (scPP) biologically protected  
a N-terminal  $\alpha$ -amine by an amide bond  
to an interconnecting peptide (I<sub>1</sub>) and  
an optional binding protein (BP) and  
55 protected at the C-terminal  
 $\alpha$ -carboxyl with an arginine (Arg)  
residue

- $$\begin{array}{l} \text{BPI}_1 - \text{scPP} - \text{Arg} = \text{recombinant single copy polypeptide} \\ \quad \quad \quad | \quad \quad \quad \text{protected at the side chain} \\ \quad \quad \quad \text{NHCOR} \quad \quad \quad \text{reactive groups (NHCOR)} \end{array}$$
- 5
- $$\begin{array}{l} \text{NH}_2 - \text{scPP} - \text{Arg} = \text{side chain protected recombinant} \\ \quad \quad \quad | \quad \quad \quad \text{single copy polypeptide with} \\ \quad \quad \quad \text{NHCOR} \quad \quad \quad \text{unprotected N-terminal } \alpha\text{-amine (NH}_2\text{)} \end{array}$$
- 10
- $$\begin{array}{l} \text{M}_1\text{NH} - \text{scPP} - \text{Arg} = \text{side chain protected recombinant} \\ \quad \quad \quad | \quad \quad \quad \text{single copy polypeptide with} \\ \quad \quad \quad \text{NHCOR} \quad \quad \quad \text{modified N-terminal } \alpha\text{-amine (NHM}_1\text{)} \end{array}$$
- 15
- $$\begin{array}{l} \text{M}_1\text{NH} - \text{scPP} - \text{COOH} = \text{N-terminally modified side chain} \\ \quad \quad \quad | \quad \quad \quad \text{protected recombinant single copy} \\ \quad \quad \quad \text{NHCOR} \quad \quad \quad \text{polypeptide with unprotected} \\ \quad \quad \quad \quad \quad \quad \text{C-terminal } \alpha\text{-carboxyl group} \end{array}$$
- 20
- $$\begin{array}{l} \text{M}_1\text{NH} - \text{scPP} - \text{COM}_2 = \text{C-terminal (COM}_2\text{) modified side} \\ \quad \quad \quad | \quad \quad \quad \text{chain protected single copy} \\ \quad \quad \quad \text{NHCOR} \quad \quad \quad \text{polypeptide} \end{array}$$
- 25
- $$\text{M}_1\text{NH} - \text{scPP} - \text{COM}_2 = \text{N and C terminally modified single copy polypeptide}$$


Another variation of the method of the invention involves C-terminal modification of a single copy polypeptide derived from a recombinantly produced multicopy polypeptide. The multicopy polypeptide is formed with multiple copies of the desired polypeptide connected with intraconnecting peptides. The intraconnecting peptide acts as a biological protecting group for the C-terminal  $\alpha$ -carboxyl reactive group of the single copy polypeptides. The recombinantly produced multicopy polypeptide is cleaved with a cleavage reagent specific for the intraconnecting peptide to form a first mixture of a single copy polypeptide with unprotected N-terminal  $\alpha$ -amine and an unprotected C-terminal  $\alpha$ -carboxyl group and a single copy polypeptide with an unprotected N-terminal  $\alpha$ -amine and an intraconnecting peptide at the C-terminal  $\alpha$ -carboxyl group. The first mixture is reacted with at least one chemical protecting agent that forms protecting groups at the reactive side chain groups and the unprotected N-terminal  $\alpha$ -amine reactive group. The

intraconnecting peptide at the C-terminal  $\alpha$ -carboxyl group is then removed by cleavage with a cleavage reagent that digests the intraconnecting peptide residues to form a side chain protected single copy polypeptide having an unprotected C-terminal  $\alpha$ -carboxyl group. The unprotected C-terminal  $\alpha$ -carboxyl group is then modified with a modifying agent. The side chain protected single copy polypeptide with modified C-terminal  $\alpha$ -carboxyl group is then deprotected to form the C-terminal modified single copy polypeptide. The reaction scheme depicting selective C-terminal modification of single copy polypeptide derived from a recombinantly produced multicopy polypeptide is as follows:

15

**Reaction Scheme II:  
Selective C-terminal Modification of a  
Single Copy Polypeptide Derived from a  
Recombinant Multicopy Polypeptide**


20



25

(1) Forming the recombinant multicopy polypeptide with intraconnecting peptide ( $\text{I}_2$ ) as biologically added protective group


30



First mixture

(2) Cleavage reagent specific for intraconnecting peptide

35



Second mixture

(3) Chemical protecting agents

40



(4) Cleavage reagent specific for removal of the C-terminal biological protecting group

45



(5) Modifying agent



(6) Deprotecting

Key

	$\text{NH}_2\text{mc}(\text{PPI}_2)_n\text{P COOH}$	= multicopy polypeptide (mcPP) intra-connected with an intraconnecting peptide ( $\text{I}_2$ )
5	$\text{NH}_2\text{scPPCOOH}$	= single copy (sc) polypeptide with unprotected N-terminal $\alpha$ -amine and C-terminal COOH and side chain groups
10	$\text{NH}_2\text{scPPI}_2$	= single copy polypeptide with unprotected N-terminal $\alpha$ -amine and C-terminal intraconnecting peptide residues
15	$\text{NHCORscPPCOOH}$	= side chain protected (NHCOR) single copy polypeptide
	$\text{NHCORscPPI}_2$	= side chain protected single copy polypeptide having C-terminal intraconnecting residues
20	$\text{NHCORscCOM}$	= side chain protected modified single copy polypeptide
	$\text{NH}_2\text{scPPCOM}$	= terminally modified single copy polypeptide

25 Other variations of the method of the invention involving the number and sequence of the steps can be utilized to achieve selective modification of the N- and/or C-terminal  $\alpha$ -carbon reactive group of a recombinantly produced polypeptide. The combination of

30 steps that will be appropriate to result in selective N- and/or C-terminal modification depends on the selection of:

- (a) the starting material - a multicopy polypeptide or fusion protein can require additional
- 35 cleavage steps to form single copy polypeptides;
- (b) whether the modification is at the N- and/or C-terminal  $\alpha$ -carbon reactive group, N- and C-terminal modification requires extra steps;
- (c) the amino acid sequence of the desired
- 40 polypeptide, especially the number of different side chain reactive groups and whether a cleavage recognition sequence is present in the sequence of the polypeptide; and

(d) the type of modification, some types of modification do not require protection of the side chain groups.

A preferred variation of the multicopy method of the invention is based upon the demifusion protein concept. The interconnecting peptide contains two unique cleavage sites and one of which is optionally the same as appears in the intraconnecting polypeptide. The binding protein is modified so that the cleavage sites of the inter- and intraconnecting peptides do not appear in the binding protein. After separation and purification of the fusion protein, cleavage with a first cleavage agent releases the demifusion protein containing multiple copies of the desired polypeptide and a short peptide sequence (i.e., the interconnecting peptide) as the biological protecting group for the N-terminal  $\alpha$ -amine. The side chains of the demifusion protein are protected. The interconnecting peptide residue acts as a protecting group for the N-terminal  $\alpha$ -amine, the copies themselves act as protecting groups for the internal N- and C-terminal groups of the internal copies and the C-terminal of the demifusion protein is protected with another amino acid such as an arginine. After protection, the cleavage agents are added to cleave the N-terminal biological protecting group if desired, to release the various copies of the desired polypeptide and to create free N-terminal amines or free C-terminal carboxylic acids as desired according to the specific nature of the intraconnecting peptide residue. Chemical modification at the N-terminal or C-terminal or both followed by removal of the protecting groups and the residue on the termini produce the desired N- or C-terminal modified polypeptide.

A. Preparation of the Starting Materials: Forming the Recombinant Polypeptide Biologically Protected at the N- and/or C-Terminal  $\alpha$ -Carbon Reactive Group

1. Selecting the Desired Peptide and the

5 Modification

A polypeptide is a polymer of amino acids linked by amide bonds having a terminal amino acid with a reactive  $\alpha$ -amine group at one end (N-terminal) and a terminal amino acid with a reactive  $\alpha$ -carboxyl group at the other end (C-terminal). A polypeptide typically has at least one reactive or functional amine group including the N-terminal  $\alpha$ -amine group. In addition, the polypeptide can have one or more reactive side chains including  $\epsilon$ -amino groups of lysine. Other amino acids have side chains with reactive or functional groups like thiol, hydroxyl, phenolic hydroxyl, imidazole and carboxylic acid groups. A recombinantly produced polypeptide is a polypeptide that is produced by isolating or synthesizing the gene for the polypeptide and introducing the gene into a vector which allows for the amplification and manipulation of expression of the gene in a host organism.

The starting material is selected, designed and then recombinantly produced. The starting material is selected according to such factors as:

- (a) the characteristics of the desired polypeptide including the desired modification, size and amino acid composition;
- (b) whether the modification is to be made at the N- and/or C-terminal amino acid  $\alpha$ -carbon reactive group requiring biologically added protecting groups at one or both ends of the molecule; and
- (c) ease of purification, to enhance purification of the recombinantly produced polypeptide a single or multicopy fusion protein can be formed.

Before the starting material of the invention is formed, the desired polypeptide is selected because of its function, size, and amino acid composition.

The function of the polypeptide selected for the method of the invention can be altered by selective modification of the N- and/or C-terminal amino acid. Modifications to the polypeptide can change the structural characteristics and/or the biological activity of the polypeptide. For example, C-terminal amidation of many small peptides, like mastoparan or the human gastrin releasing peptide, enhances the biological activity of these peptides. In another example, N-terminal reaction with a synthetic organic moiety or a synthetic organic/oligopeptide moiety significantly alters the biological activity of these peptides. Moreover, addition of peptides having D- or L-amino acids can provide for targeting of the polypeptide to a specific cell type, changing the rate of breakdown and clearance of the peptide, increasing the biological potency and increasing the biological activities of the polypeptide. Addition of D-amino acids or peptides or derivatives of amino acids can also result in the formation of antagonists. The choice of polypeptide and modification can be made based upon the desired change of the structural or biological activity of the peptide. The especially preferred modification is C-terminal amidation of a peptide.

Several examples of modified polypeptides and the changes in biological activity associated with this modification are described in Kirk-Othmer Encyclopedia of Chemical Technology, 4th Edition, Vol. 12, pp. 603-617 (1991), which is hereby incorporated by reference.

The size of the selected polypeptide can range from a peptide of about 4 amino acids to a polypeptide of about 4000 amino acids (about 500,000 daltons). The larger polypeptides are typically recombinantly produced as a single copy fusion protein or polypeptide. Smaller peptides having 50 amino acids or less are preferably produced as multicopy fusion proteins or polypeptides.

Especially preferred are small biologically active peptides having 50 amino acids or less.

The amino acid composition of the desired polypeptide can have a multiplicity of side chain functional reactive groups, but the method is preferably directed to polypeptides having one or two types of reactive side chain groups. For example, especially preferred polypeptides are those having only  $\epsilon$ -amine groups as reactive side chain groups. Other especially preferred polypeptides are those having  $\epsilon$ -amino and hydroxyl or carboxyl side chain groups. Many small biologically active peptides, like the magainin polypeptides, have limited types of functional or reactive side chain groups.

Specific examples of polypeptides having one or two types of reactive side chain groups include the magainin polypeptides I, II and III, as disclosed by Zasloff et al. in U.S. Patent No. 4,810,777 (issued March 7, 1989); and wound healing peptide like Ala-Phe-Ser-Lys-Ala-Phe-Ser-Lys-Ala-Phe-Ser-Lys-Ala-Phe-Ser-Lys-Ala-Phe-Ser-Lys (SEQ ID NO:1), as disclosed by Berkowitz et al. in U.S. Patent No. 5,045,531 (issued September 3, 1991). These disclosures are hereby incorporated by reference.

Other examples of suitable polypeptides include the magainin polypeptide 1, magainin polypeptide 2, magainin polypeptide 3, wound healing peptides, myosin light chain kinase inhibitor, substance P, mastoparan, mastoparan X, human amylin, rat amylin, Icaria chemotactic peptide, carassin, human gastrin releasing peptide, kemptamide, myosin kinase inhibiting peptide, melettin, [Leu<sup>5</sup>]-enkephalamide, [Met<sup>5</sup>]-enkephalamide, metropenamide, ScP<sub>8</sub>, allatostatin 1, allatostatin 3, crustacean cardioactive peptide, FMRF (molluscan cardioexcitatory neuropeptide), FMRF-like peptide F1, neuromedin B, bombesin, leukopyrokinin, alytesin, corazonin and littorin.

Once the desired polypeptide and modification is selected, the starting material can be designed and recombinantly produced so that the N- and/or C-terminal  $\alpha$ -carbon reactive group has a biologically added protecting group.

2. **Selecting The Biologically Added Protecting Groups To Be Added to the N- and/or C-Terminal  $\alpha$ -Carbon Reactive Group of the Polypeptide**

Before the starting material is formed, the biologically added protecting groups are selected. The biologically added protecting groups can be a polypeptide, peptide and/or amino acid linked by an amide bond connection to the N- and/or C-terminal  $\alpha$ -carbon reactive group. The type of bond formed is generally irreversible and the sequence of the biological protecting group contains at least one site that is cleavable enzymatically or chemically so that the biological protecting group can be selectively removed. Preferably, the sequence of the biologically added protecting group is not present in the desired polypeptide. When both the N- and C-terminal  $\alpha$ -carbon reactive groups are protected with the biologically added protecting groups, the biologically added protecting group at the N-terminal  $\alpha$ -carbon reactive group is preferably different from the group at the C-terminal  $\alpha$ -carbon reactive group to allow for sequential cleavage of the N- and C-terminal biologically added protecting group.

The biologically added protecting group has at least one cleavage site to provide for removal of all or part of the biological protecting group. Specific examples of peptides and amino acids that can serve as a cleavage site in biological protecting groups and the cleavage enzymes or conditions are provided in Table 1.

TABLE 1

	<u>Enzymes for Cleavage</u>	<u>Biological Protecting Groups</u>	<u>DNA Seq.</u>
5	Enterokinase	(Asp),Lys (SEQ ID NO:2)	GACGACGACGATAAA (SEQ ID NO:12)
10	Factor Xa	IleGluGlyArg (SEQ ID NO:3)	ATTGAAGGAAGA (SEQ ID NO:13)
	Thrombin	ArgGlyProArg (SEQ ID NO:4)	AGAGGACCAAGA (SEQ ID NO:14)
15	Ubiquitin Cleaving Enzyme	ArgGlyGly	AGAGGAGGA
20	Renin	HisProPheHisLeu- LeuValTyr (SEQ ID NO:5)	CATCCTTTTCATC- TGCTGGTTTAT (SEQ ID NO:15)
	Trypsin	Lys or Arg	AAA OR CGT
25	Chymotrypsin	Phe or Tyr or Trp	TTT or TAT or TGG
	Clostripain	Arg	CGT
30	S. aureus V8	Glu	GAA
	<u>Chemical Cleavage</u>	<u>Biological Protecting Groups</u>	<u>DNA Seq.</u>
35	(at pH3)	AspGly or AspPro	GATGGA
	(Hydroxylamine)	AsnGly	AATCCA
40	(CNBr)	Methionine	ATG
	BNPS-skatole	Trp	TGG
45	2-Nitro-5- thiocyanobenzoate	Cys	TGT

The biological protecting group can contain more than one enzymatic and/or chemical cleavage site, and preferably contains at least one site cleaved by a chemical reagent and at least one site cleaved by an enzyme. Alternatively, the biological protecting group can have at least two different enzymatic sites of

cleavage or at least two different chemical cleavage sites. A specific example of a biological protecting group having multiple cleavage sites is exemplified by the following peptide (SEQ ID NO:6):

5           Phe Val Asp Asp Asp Asp Lys<sub>A</sub> Phe Val Asn<sub>B</sub>  
           Gly Pro Arg<sub>C</sub> Ala Met<sub>D</sub> Phe Val Asp Asp Asp  
           Asp Lys<sub>A</sub> Val Asn<sub>B</sub> Gly Pro Arg<sub>C</sub> Ala Met<sub>D</sub> Ala

10                   <sub>A</sub> = cleavage site for enterokinase  
                     <sub>B</sub> = cleavage site for hydroxylamine  
                     <sub>C</sub> = cleavage site for thrombin  
                     <sub>D</sub> = cleavage site for cyanogen bromide

The biological protecting group with multiple cleavage sites can also serve as an interconnecting or intraconnecting peptide. While not in any way meant to  
 15 limit the invention, the combination of chemical and enzymatic cleavage sequence in biologically protected group provides for advantages in purification and cleavage efficiency.

The biological protecting group can also be a  
 20 combination of a polypeptide and a peptide like, for example, in a recombinant single copy fusion protein. A recombinant single copy fusion protein has three tandemly coupled segments. The first segment is a binding protein, the second segment is an  
 25 interconnecting peptide, and the third segment is the single copy polypeptide. The interconnecting peptide connects the binding protein to the single copy polypeptide at either the N- or C-terminal  $\alpha$ -carbon reactive group. The interconnecting peptide has at  
 30 least one chemical or enzymatic cleavage site and, preferably, has a sequence not found in the single copy polypeptide. The interconnecting peptide and optionally the binding protein as the biologically added protecting group at the N-terminal  $\alpha$ -amine or C-terminal  $\alpha$ -carboxyl  
 35 group and also provide for purification of the recombinantly derived single copy polypeptide.

Another example is recombinant multicopy fusion protein composed of three tandemly coupled segments.

The first segment is a binding protein, the second segment is an interconnecting peptide, and the third segment is a multicopy polypeptide. The interconnecting peptide connects the binding protein to the N- or C-terminal  $\alpha$ -carbon reactive group of the multicopy polypeptide. The multicopy polypeptide contains several copies of the single copy polypeptide connected by an intraconnecting peptide. The inter- and intraconnecting peptides both have at least one site that is cleavable and preferably do not contain amino acid sequence present in the single copy polypeptide. The interconnecting peptide and the intraconnecting peptide can act as biological protecting groups of the N- and/or C-terminal  $\alpha$ -carbon reactive groups of the single or multicopy polypeptide. When both the C-terminal and N-terminal  $\alpha$ -carbon reactive groups are to be modified, preferably the inter- and intraconnecting peptide have different cleavage sites to provide for sequential cleavage.

Once the polypeptide and the desired modification are selected, the protecting groups to be biologically added to the N- and/or C-terminal  $\alpha$ -carbon reactive groups are selected. The factors for selecting the biologically added protecting groups to be combined with the desired polypeptide include: (a) the amino acid sequence of the single copy polypeptide; (b) whether the polypeptide is going to be recombinantly produced as a single or multicopy polypeptide; (c) whether a single or multiple cleavage site is desired; (d) whether enzymatic or chemical cleavage is desired; (e) whether a fusion protein is desired to provide for purification; and (f) compatibility of the amino acid sequence of the biological protecting group with the chemical protecting agents.

3. **Forming the Recombinant Single or Multicopy Polypeptide Protected with One or More Biologically Added Protecting Groups at the N- and/or C-Terminal  $\alpha$ -Carbon Reactive Groups By Standard Recombinant DNA Methodology**

5 The single or multicopy polypeptide or fusion protein starting material of the method of the invention is formed by standard recombinant DNA methods. The gene sequence for the desired polypeptide or a portion  
10 thereof can be cloned or, in the case of a smaller peptide, synthesized by automated synthesis. The gene sequence encoding the biologically added protecting group is synthesized by automated oligonucleotide synthesis. The gene sequence for the biologically added  
15 protecting group is combined with the gene sequence for a single or multicopy polypeptide or a portion thereof so that the single or multicopy polypeptide produced has at least one cleavable biologically added protecting group at the N- and/or C-terminal  $\alpha$ -carbon reactive  
20 group.

The gene sequence for the biologically added protecting group encodes a polypeptide, peptide, amino acid, or a combination thereof. Preferably, the gene sequence encodes a peptide of less than about 50 amino  
25 acids and provides for one site of cleavage by a chemical reagent and at least one site of enzymatic cleavage. Once the biological protecting group is selected, the DNA sequence is formed by automated synthesis and combined with the gene sequence for the  
30 single or multicopy polypeptide by standard recombinant DNA methodologies. Specific examples of the DNA sequences that correspond to amino acid cleavage sites are provided in Table 1. The DNA sequences encoding chemical and enzymatic cleavage sites can be combined  
35 into a gene sequence for a single biological protecting group by automated oligonucleotide synthesis.

The single or multicopy polypeptide can also be formed as a recombinant single or multicopy fusion protein. The fusion protein has three tandemly coupled

segments. The first segment is a binding protein, which exhibits strong, reversible binding to a ligand for the binding protein, preferably a reversible inhibitor for an enzyme or enzyme-like binding protein. The second  
5 segment is an interconnecting peptide, which is selectively cleavable by an enzyme and/or chemical technique. The third segment is the single or multicopy polypeptide. The binding protein with interconnecting peptide provides for purification of the  
10 recombinantly produced single or multicopy polypeptide and acts as a biological protecting group for the N- or C-terminal  $\alpha$ -carbon reactive group. Although the binding protein and interconnecting peptide can both serve as the biological protecting group, in a preferred  
15 embodiment, the interconnecting peptide contains two selective cleavage sites so that the binding protein can be removed and the interconnecting peptide will remain. After purification in this preferred embodiment, the binding protein can be cleaved to leave a peptide  
20 fragment, i.e., the interconnecting peptide, which serves as the biological protecting group. The resulting demifusion protein eliminates the need to carry the binding protein peptide sequence through the remaining steps and preserves the biological protecting  
25 group benefits derived from the binding protein. Single or multicopy fusion proteins are produced by standard recombinant DNA methodology, as discussed in co-pending application Serial No. 07/552,810, which is hereby incorporated by reference. Formation of recombinantly  
30 produced single or multicopy fusion proteins is described.

The binding protein segment of the fusion protein generally is an antibody, an antibody L or H chain, an enzyme, a lectin, avidin or any expression  
35 protein having a binding site for selective binding to a ligand such as an antigen, a substrate, an inhibitor, a sugar or biotin. Preferably, the binding protein is an

enzyme-like protein including but not limited to an enzyme or a truncated, altered or modified functional version thereof (hereinafter the modified functional version). The binding is preferably strong and  
5 selective. Preferably for an enzyme the ligand is a reversible inhibitor for the enzyme-like protein.

Especially preferred embodiments of the enzyme binding protein include carbonic anhydrase derived from any source, especially mammalian or human, and a  
10 modified functional version thereof which will bind with the inhibitor, sulfanilamide or derivatives thereof. An especially preferred embodiment of the modified carbonic anhydrase enzyme is a functional version which (I) does not contain methionine, (II) has all or some glutamates  
15 replaced by another amino acid, preferably aspartate, (III) has all or some arginines replaced by another amino acid, preferably lysine, (IV) has asparagines next to glycine replaced by another amino acid, preferably glutamine or glycine changed to alanine, (V) has  
20 methionine replaced by another amino acid, preferably leucine, (VI) has cysteine replaced by another amino acid, preferably serine, and (VII) has methionine at position 240 replaced by another amino acid, preferably leucine or serine and isoleucine.

25 Antibodies or individual chains, regions or fragments thereof, as characterized above, and other proteins, which will strongly, biospecifically and reversibly bind to a low molecular weight ligand, can perform the same function in the same way to reach the  
30 same result as the enzyme-like protein in the context of the protein purification construct, and consequently are also preferred within the invention as binding proteins. For antibodies or the corresponding chains, regions or fragments, the ligand is a low molecular weight antigen,  
35 preferably an aromatic moiety such as dinitrophenol.

Suitable binding proteins and their corresponding ligands include those provided in Table 2.

TABLE 2

	<u>Binding Protein</u>	<u>Ligand</u>	<u>Kd</u>	<u>Ref.</u>
	Xanthine Oxidase	Allopurinol	strong	1
5	Adenosine deaminase	Coformycin	<1.2E-10	1
	Adenosine deaminase	Deoxycoformycin	2.5E-12	2
	Adenosine deaminase	erythro-9-(2-hydroxy-3 nonyl) adenine	1.6E-9	2
	Dihydrofolate reductase	Methotrexate	1.2E-9	4
10	Dihydrofolate reductase	Methotrexate	2.3E-9	5
	Dihydrofolate reductase	Aminopterin	3.7E-9	5
	Dihydrofolate reductase	Trimethoprin	4.6E-9	5
	Ribulose biphosphate carboxylase	2 carboxyarabirital 1,5 biphosphate	1E-14	6
15	Pepsin	Pepstatin	10E-9	
	Calmodulin	Melittin	3E-9	7
	Calmodulin	Various peptides	0.2E-9	7
	Cholesterol esterase	Borinic acid	0.1E-9	8
	Carbonic anhydrase II	Sulfanilamide	4.6E-7	3
20	Carbonic anhydrase II	Acetazolamide	6 E-10	3

E is times ten to the negative exponent indicated.

References Cited in Table 2

- 25
1. Cha et al., Biochemical Pharm., 24, 2187-2197.
  2. Agarwal et al., Biochemical Pharm., 26, 354-367 (1977).
- 30
3. Taylor, P.W. et al., Biochemistry, 9, 2638 (1970).
  4. Cha et al., Biochemical Pharm., 30, 1507-1515 (1981).
  5. Williams et al., Biochemical Pharm., 29, 589-595 (1980).
- 35
6. Pierce, J., Tolbert, N.E., Barker, R., Biochem., 19:934-942 (1980).
  7. Degrado et al., J. of Cellular Biochem., 29, 83-93 (1989).
- 40
8. Sutton et al., BBRC, 134, 386-392 (1986).

Other suitable binding proteins include  $\beta$ -galactosidase as described by Hanada et al., J. Biol. Chem., 263:7181 (1988); flagellin protein as described by Stahl et al., U.S. Patent No. 4,801,526 (issued  
5 January 31, 1989); ubiquitin, Yoo et al., J. Biol. Chem., 264:17078 (1989); protein A, B. Nillson et al., EMBO Journal, 4:1075 (1985); streptavidin, Meade et al., PCT/US 85/01901 (1986); and the flag peptide, K. Itakura et al., Science, 198:1056 (1977), which are hereby  
10 incorporated by reference.

The choice of the interconnecting or intraconnecting peptide for the single or multicopy fusion protein depends upon the choice of cleavage enzyme and product peptide sequence. In general, the  
15 interconnecting peptide sequence constitutes any peptide sequence that uniquely reacts with a highly specific cleavage enzyme or by a highly specific chemical reagent cleavage, or combination thereof, like those shown in Table 1. The interconnecting or intraconnecting peptide  
20 is connected to the N- and/or C-terminal  $\alpha$ -carbon reactive group and also serves as a biologically added protecting group.

Generally, the interconnecting peptide, and the intraconnecting peptide fragments will have different  
25 amino acid sequences so that they can be sequentially rather than simultaneously cleaved. The amino acid sequences can be chosen also so that the cleavage sequence does not duplicate any amino acid sequence of the product peptide(s). Alternatively, the cleavage  
30 specific amino acids in the peptide can be blocked or protected from the cleavage reaction as provided in the method of the invention. These peptide and/or amino acid connecting fragments can be chosen from the same group of amino acid unit sequences for example, those  
35 listed in Table 1. The factors to consider in choosing these peptide connecting fragments are similar to those

for selecting other biological protecting groups and include the following:

- a) The amino acid sequence of the product peptides;
- 5 b) Whether the polypeptide is a single or multicopy polypeptide;
- c) Whether a single or multi cleavage site is desired;
- 10 d) Whether enzymatic or chemical cleavage is desired;
- e) Whether the intra- and interconnecting peptides and the gene fragments coding for them are positioned and altered to provide for diversity in the gene sequence for the variable fused peptide.
- 15 This diversity allows efficient expression of multiple units of a small peptide. It has been discovered that a continuously repetitive genetic sequence will often be rearranged or deleted by the host organism prior to recombination.
- 20 The recombinantly produced single or multicopy polypeptide with N- and/or C-terminal biologically added protecting groups is produced by standard recombinant DNA methods. An expression cassette can be formed by combining the gene for the single or multicopy
- 25 polypeptide and the gene encoding the desired biological protecting group with transcriptional and translational control regions. For example, the recombinant gene encoding the fusion protein incorporates three DNA segments coding for the binding protein, the
- 30 interconnecting peptide and the single or multicopy polypeptide. The segments are arranged so that either the binding protein gene fragment or the single or multicopy polypeptide fragment can be read first. It is preferred to construct the fusion protein gene so that
- 35 the binding protein gene fragment is read first. The gene segments can be synthetic or derived from natural sources. The fusion protein gene is combined with

transcriptional and translational control regions to form an expression cassette.

An expression vector containing the expression cassette is capable of providing for expression of the  
5 biologically protected single or multicopy polypeptide in prokaryotic or eukaryotic cells. The expression vector incorporates the single or multicopy polypeptide gene and base vector segments such as the appropriate regulatory DNA sequences for transcription, translation,  
10 phenotyping, temporal or other control of expression, RNA binding and post-expression manipulation of the expressed product. The expression vector generally will include structural features such as a promoter, an operator, a regulatory sequence and a transcription  
15 termination signal. The expression vector can be synthesized from any base vector that is compatible with the host cell or higher organism and will provide the foregoing features. The regulatory sequences of the expression vector will be specifically compatible or  
20 adapted in some fashion to be compatible with prokaryotic or eukaryotic host cells or higher organisms. Post-expression regulatory sequences, which cause secretion of the fusion protein can be included in the eukaryotic expression vector. It is especially  
25 preferred that the expression vector exhibit a stimulatory effect upon the host cell or higher organism such that the fusion protein is overproduced relative to the usual biosynthetic expression of the host.

In one preferred scheme for construction of the  
30 vector, the DNA segment for the binding protein, for example the human gene for carbonic anhydrase II, (the binding protein gene) is inserted into a base plasmid which is compatible with the host cell to be transformed. The base plasmid contains the necessary  
35 regulatory sequences for high level expression of genes placed downstream.

A synthetic DNA sequence coding for the interconnecting peptide is then inserted near the 3' end of the binding protein gene. A restriction enzyme site near the 3' end of the binding protein gene should be present to enable insertion of this DNA sequence for the inter-connecting peptide. Also, at least one convenient restriction enzyme site (intermediate vector restriction site) should be designed into the synthetic DNA sequence for the interconnecting peptide so that DNA segments coding for the variable fused polypeptide can later be inserted in the correct reading frame. If no such sites are already present, they can be introduced at this point in the scheme by a site-specific mutagenesis after standard procedures described in Sambrook, J., Fritsch, E.F. and Maniatis, T., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989), the disclosure of which is incorporated herein by reference.

The resulting vector construct is the intermediate base vector for the in situ construction of the fusion protein gene integrated into the larger vector. Any naturally occurring or synthetic DNA sequence encoding a single or multicopy polypeptide can be inserted into the intermediate vector restriction site to yield a fusion protein gene integrated into the expression vector. Proper insertion and reading frame alignment can be verified by known techniques such as sequencing the junction region between the binding protein gene and the DNA sequence for the variable fused polypeptide according to methods described in Sambrook et al.

In a second alternative, after ligating together any two adjacent DNA segments, the resulting intermediate gene can be transferred to the base vector by the restriction and ligation methods described above. The third DNA segment (i.e., the binding protein gene or variable fused polypeptide gene) can be inserted into

the base vector carrying the intermediate gene pursuant to the Sambrook techniques including construction of appropriate restriction sites, if needed, and ligation procedures described above. All protocols for  
5 restriction, insertion, ligation and the like follow standard procedures such as those described by Sambrook, cited supra.

Preferred base vectors include any plasmid that is compatible with the particular host, is stable in  
10 that host and allows for a positive selection of the transformed host. Such vectors include, for example, pTZ18/19U/R or pPL-lambda as well as those characterized in P.H. Pouwels, B.E. Enger-Valk, and W.J. Branimer, Cloning Vectors, Elsevier Science Pub. (1985) the  
15 disclosure of which is incorporated herein by reference.

The final recombinant expression vector will carry an appropriate promoter, a sequence coding for a ribosome binding site, phenotype genes for selection, and regulatory regions for transcription, translation  
20 and for post-translational intracellular manipulation of the resulting biologically protected single or multicopy polypeptide.

The expression vector is introduced into prokaryotic or eukaryotic host cells by standard methods  
25 like calcium phosphate precipitation, electroporation and microinjection. Isolation of host cells transformed with the final recombinant expression vector is accomplished by selecting for the phenotype or other characteristic that is designed into the recombinant  
30 vector. Generally, such selection characteristics include antibiotic resistance or complementation of deficient functions in the host. Preferred phenotype genes for the recombinant vector of the invention include antibiotic resistant phenotypes, essential amino  
35 acid phenotypes and other essential compound phenotypes.

Preferably, an inducible expression system is used so that the selected, transformed host cell will be

grown to an early- to mid-logarithmic phase and treated with an induction compound to cause the biologically protected single or multicopy polypeptide to be produced. Typically, incubation will be continued for up to several hours (the most appropriate incubation time for each single or multicopy polypeptide is determined by sampling at differing times during a test incubation), at which point the cells are harvested and lysed. If the transformed host cell is designed to secrete the biologically protected single or multicopy polypeptide, the culture is grown until an appropriate and/or desired concentration of the polypeptide is present in the culture medium. If the host cell is one that will contain dissolved polypeptide in its cytoplasm, the culture is grown until it reaches optimum maturity. The mature culture is then lysed with an appropriate agent to release the polypeptide. If the polypeptide or fusion protein is deposited as insoluble granules in the host cell, the mature cell culture is lysed and the released insoluble granules are dissolved in chaotropic agents. This incubation, growth and lysing process can be conducted in a batch or continuous manner.

The transformed cells are capable of expressing polypeptides containing multiple copies of the polypeptides up to a molecular weight of the largest protein naturally expressed by the cell. For prokaryotic cells, this means that the size of the recombinant protein expressed usually will be smaller than about 500,000 daltons. This is the size of certain enzymes naturally produced, for example by E. coli and Bacillus subtilis, as disclosed by B. Lewin, in Genes, 4th Edition, pages 606-607, Oxford Press, New York, NY (1990), which is incorporated herein by reference. Although eukaryotic cells utilize proteins of a larger size than about 500,000 daltons, typically those larger proteins are expressed as subunits and assembled by

post-expression manipulation in such cells. Examples of such larger proteins include hemoglobin and antibodies. Although not meant in any way to limit the invention, it is believed that the expression of very large proteins  
5 (greater than 500,000 daltons) is limited by the translational error frequency which approaches 50% during synthesis of a very large protein.

Other factors, as well, can influence the control and extent of expression of the fusion protein  
10 in cells transformed with recombinant expression vector. Optimal expression of a multicopy expression cassette or vector can be achieved if the recombinant expression vector is constructed using these factors.

The first factor is that the gene sequence for  
15 the multicopy protein should have variations in the gene sequence. This variation avoids a high degree of repetition along the gene sequence and the protein sequence. Such repetition endangers both the gene and expressed fusion protein because the cell will recognize  
20 the repetition sequence and excise or assimilate the sequence or protein.

The second factor is that the binding protein gene segment should have a size like that for an enzyme. The size minimizes or prevents variation of  
25 translational efficiency due to the needed variation of the gene segment for the desired protein. The latter gene segment variation is important for the reason mentioned above. If the leader sequence is short, the cell will recognize a variation in the tail sequences as  
30 a signal to lower the expression efficiency for the protein.

The third factor is that certain polypeptides present in the multicopy alternative achieve a greater increase in yield efficiency than others. This  
35 efficiency depends on the ratio of the weight of the binding protein to the weight of the desired protein. Above a certain number of copies, the yield efficiency

does not appreciably increase for total molecular weights greater than 250,000 daltons.

The fourth factor is that the expressed protein should be soluble or form granules (inclusion bodies) in the cytoplasm of the transformed cell. Purification and post-expression manipulation of the fusion protein is more readily accomplished when the fusion protein is soluble or forms granules.

The fifth factor is that a strongly bound inhibitor/enzyme couple is employed to separate and purify the fusion protein. In order to achieve this goal, the fusion protein should maintain essentially the same binding constant between the enzyme and its inhibitor as is exhibited by the free enzyme in the inhibitor.

Although the formation of a recombinantly produced single or multicopy fusion protein has been described, the techniques described above can also be used to add a different polypeptide, peptide and/or amino acid as a biologically added protecting group to the N- and/or C-terminal end of the single or multicopy polypeptide. For example, in the method described above if the binding protein is eliminated, the interconnecting peptide is sufficient itself as a biologically added protecting group. In another example, the biologically added protecting group can be as simple as a single amino acid added to the N- and/or C-terminal amino acids of the single copy polypeptide.

In an alternative version, the single or multicopy polypeptide can be recombinantly produced as a truncated polypeptide having only a portion of the amino acid sequence of the desired polypeptide. The recombinantly produced truncated single or multicopy polypeptide preferably lacks about 1 to about 10 amino acids at the N- or C-terminal end of the molecule. The gene for the truncated single or multicopy polypeptide can be synthesized by automated synthesis or can be

obtained by restriction endonuclease cleavage of entire gene sequence so that the coding sequence for up to 10 amino acids is removed. The truncated gene can be combined with the gene sequences for the binding protein and interconnecting peptide or any other biologically added protecting group as described herein. The amino acids missing from the truncated single or multicopy polypeptide are later replaced by modification reaction.

The preferred starting material for the C- and/or N-terminal selective modification method of the present invention is a multicopy fusion protein having several copies of polypeptide tandemly linked and intraconnected via an amino acid and interconnected via a peptide to the binding protein. An example of the preferred multicopy fusion protein is comprised of a human carbonic anhydrase II binding protein, optionally modified by conversion of the methionine 240 to leucine, isoleucine interconnected by an enterokinase recognition site or cyanogen bromide and hydroxyl amine recognition sites to the N-terminal  $\alpha$ -amine of a multicopy polypeptide having three tandemly linked copies of the polypeptide mastoparan intraconnected with the amino acid arginine, and having a C-terminal arginine. The human carbonic anhydrase II binding protein option enables removal of the binding protein after its usefulness in separation and purification is finished. This option eliminates the chemical processing of the binding protein sequence that does not form part of the final desired polypeptide. The benefits include but are not limited to increased solubility of the demifusion protein, increased facility to manipulate the demifusion protein in subsequent processing, increased ability to perform separation and purification of the demifusion protein and early elimination of peptide sequences not appearing in the final product.

An expression cassette for the human carbonic anhydrase mastoparan fusion protein is formed as

follows. The especially preferred gene for the human carbonic anhydrase II binding protein is obtained as described in copending application Ser. No. 07/552,810. When employing the hCAII gene, at least a portion  
5 representing the functional fragment of the enzyme is modified as follows: (a) the hCAII asparagine-glycine peptide sequence is changed; the asparagine is changed to glutamine or glycine is changed to alanine; and (b) the sequence for the last three terminal amino acids is  
10 deleted. Optionally, the hCAII is further modified to convert methionine 240 to leucine, isoleucine or serine. (Mini modified hCAII).

The modified hCAII gene sequence can be inserted into an expression vector which is compatible  
15 with E. coli. Cleavage of the DNA sequence at a site downstream from the regulatory portion of the vector followed by insertion of the gene through blunt- or sticky-end ligation forms the recombinant vector. The insertion is downstream from the promoter sequences that  
20 provide for expression in the host cells. The promoter is preferably the T7 promoter. The T7 promoter is recognized by a chromosomally encoded T7 RNA polymerase induced by isopropyl-thiogalactoside.

A short DNA fragment coding for the inter-  
25 connecting peptide is inserted near the 3' or 5' end of the intact or partial hCA gene (intraconnecting peptides are discussed below). In a preferred version, the peptide sequence recognized by enterokinase or the peptide sequences recognized by cyanogen bromide (Met)  
30 and hydroxylamine (Asn) is inserted at the 3' terminal of the carbonic anhydrase. Preferably, the chemical recognition sequence is spaced with Gly so that the sequence reads: Met-Gly-Asn.

The gene fused onto the carbonic anhydrase  
35 II-enterokinase recognition site construct encodes three copies of the mastoparan sequence separated by Arginine residues (45 amino acids including C-terminal arginine).

The amino acid sequence for mastoparan is Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu (SEQ ID NO:7). This gene is prepared synthetically by the method of multiple complimentary oligonucleotide synthesis as described by S. Beaucage et al., Tetra. Letters, 221:859 (1981), and is designed using optimal codon usage for E. coli and contains unique and useful restriction endonuclease sites. The synthetic gene is inserted into the expression vector immediately downstream from the enterokinase recognition site by standard recombinant DNA methodology.

E. coli cells are transformed with the expression vector and transformed cells are selected. The expression of the protein in the cells is induced with isopropyl-thiogalactoside. Once sufficient protein has accumulated, the cells are lysed and the fusion protein purified.

#### 4. Purification of Single or Multicopy Fusion Protein

The recombinant single or multicopy polypeptide produced as a fusion protein allows for easy purification by affinity chromatography. The fusion protein produced in the transformed cells can be soluble in the cells or insoluble in inclusion bodies. Soluble fusion protein is obtained by lysis of the transformed cells to form a crude cell lysate. The crude cell lysate can be further purified by methods including ultrafiltration and ion exchange chromatography before purification by affinity chromatography. Insoluble fusion protein in inclusion bodies is also purified by similar methods.

To perform affinity purification, the crude mixture of materials is combined with an immobilized ligand for the binding protein. Examples of the binding protein, corresponding ligand and dissociation constants are given in Table 2. For the preferred carbonic anhydrase enzyme, or the preferred modified or mini

modified carbonic anhydrase enzyme, the ligand is sulfanilamide or a benzene sulfonamide derivative. Immobilization of the ligand on a solid support can be accomplished by the methods of W. Scouter, Methods Enzymol., 34, 288-294 (1974); S. Marcus, Methods Enzymol., 34, 377-385 (1974); A. Matsura et al., Methods Enzymol., 34, 303-4 (1974); R. Barker, Methods Enzymol., 34, 317-328 (1974); I. Matsumoto, Methods Enzymol., 34, 324-341 (1974), J. Johansen, Carlsberg Res. Commun., 14, 73 (1976) and G. S. Bethell et al., J. Biol. Chem., 254, 2572-2574 (1979); the disclosures of which are incorporated herein by reference. The fusion protein binds to the immobilized ligand through the reversible affinity of the binding protein for its ligand. The remaining constituents and debris of the crude mixture of materials can then be removed by washing or similar techniques.

Two routes can be employed for further purification of the fusion protein. According to the first route, the single or multicopy fusion protein is dissociated intact from the immobilized ligand by washing with a strong competing ligand solution. Examples include cyanides, pseudocyanides such as thiocyanides, perchlorates, halide and similar strong Lewis bases.

According to the second route, the immobilized single or multicopy fusion protein is contacted directly with cleavage reagent to release the single or multicopy polypeptide. To isolate the single or multicopy polypeptide in the second route, its mixture with cleavage enzyme can be combined with a means for molecular weight selection (e.g. partition chromatography dialysis, filtration based on molecular size or high pressure liquid chromatography on a "particle exclusion" base or ion exchange chromatography) such that the high molecular weight cleavage enzyme is separated from the free variable

fused peptide. Or, the mixture can be combined with an immobilized affinity material for the cleavage enzyme.

The cleavage enzyme chosen will depend upon the interconnecting peptide chosen. Examples of cleavage  
5 enzymes and their cleavage sites are given in Table 1.

The purification methods described above yield the starting materials for the method of the invention: a single copy fusion protein, a multicopy fusion protein, a single copy polypeptide, a multicopy  
10 polypeptide, or a truncated single or multicopy polypeptide. In a preferred embodiment, the single and multicopy polypeptides are recombinantly produced from a fusion protein. Both single copy and multicopy polypeptides can be recombinantly produced with  
15 additional residues at the N-terminal and/or C-terminal ends of the molecule without the presence of a binding protein or interconnecting peptide.

In a preferred version, the human carbonic anhydrase, modified or mini-modified human carbonic  
20 anhydrase multicopy mastoparan fusion protein is isolated from cell lysates of transformed E. coli by ultrafiltration followed by ion exchange chromatography. The cell lysate material is then loaded onto an affinity column containing sulfanilamide. The bound fusion  
25 protein is then released from the affinity column by washing with potassium thiocyanate. If carbonic anhydrase, modified carbonic anhydrase or mini-modified carbonic anhydrase is used, the purified fusion material is then digested with enterokinase, and the multicopy  
30 polypeptide is purified from the carbonic anhydrase binding protein by ultrafiltration. The purified multicopy polypeptide is composed of 3 copies of the mastoparan intraconnected by arginine residues and has a C-terminal arginine residue and an unprotected  
35 N-terminal  $\alpha$ -amine and other side chain groups. If the carbonic anhydrase binding protein is a mini-modified version, the purified fusion material is then digested

first with cyanogen bromide to cleave the carbonic anhydrase residue from the remainder of the fusion protein. The resultant demifusion protein is a purified multicopy polypeptide composed of three copies of the mastoparan that are intraconnected by arginine residues and has a C-terminal arginine residue and an N-terminal Asp<sub>4</sub> Lys sequence or a Gly Asn sequence protecting the N-terminal  $\alpha$ -amine and has unprotected side chain groups.

10 B. Cleavage and Reaction of the Starting Materials With Chemical Protecting Agents

In order to selectively modify the desired recombinant polypeptide at the N- and/or C-terminal  $\alpha$ -carbon reactive groups, the other reactive side chain are protected by reaction with up to three chemical protecting agents. The biologically added protecting group at N- and/or C-terminal  $\alpha$ -carbon is cleaved to provide an unprotected reactive N- and/or C-terminal  $\alpha$ -carbon group available for modification.

20 The number and sequence of the cleaving and reacting steps can vary depending on the starting material and modification. In some cases, the reaction scheme is conducted by reacting the starting material with the chemical protecting agent(s) first and then cleaving with a cleavage reagent specific for the N- and/or C-terminal biological protecting group. For example, if the starting material is to be modified at the N-terminal amino acid or if the cleavage site of the biologically added protecting group is present in the desired polypeptide, then the starting material is protected first and cleaved second. In other cases, the starting material is cleaved first and then reacted with up to three chemical protecting agents. For example, for modification at the C-terminal amino acid the starting material is cleaved and then reacted with the chemical protecting agents.

Other variations in the number and sequence of the cleaving and reacting steps are possible. A

reaction scheme can be selected according to the factors provided in Table 3.

**TABLE 3**


	<u>Factor</u>	<u>Present In Starting Material</u>	<u>Method</u>
5			
10	1. Is the cleavage recognition sequence of the biological protecting group present in the amino acid sequences of the polypeptide?	Yes	React with chemical protecting agents and then cleave
15		No	Can go either way
20	2. Is the N-terminal amino acid to be modified?	Yes	React with chemical protecting agents, then cleave.
25		No	Cleave and then react with chemical protecting agents
30	3. Is the starting material a multicopy fusion protein?	Yes	Two cleavage steps required - one at the inter- and one at the intraconnecting peptides.
35	4. Are both N- and C-terminal amino acids to be modified?	Yes	Extra steps of cleavage and modification required.
40	5. Does the modification reaction require protection of reactive side chain groups?	Yes	React with chemical protecting agent before modification.
45		No	Cleave and then modify. No reaction with chemical protecting agent required.

Once a particular starting material has been selected and formed, the steps of the reaction scheme can be selected by according to the factors in Table 3.

For example, for N-terminal modification of the preferred multicopy fusion protein, the following

reaction scheme is selected. The preferred multicopy fusion protein is three copies of the mastoparan polypeptide: intraconnected by arginine residues and interconnected by the enterokinase recognition peptide to carbonic anhydrase and having a C-terminal arginine residue or the three intraconnected mastoparan copies are interconnected by a methionine glycine asparagine residue to the mini-modified carbonic anhydrase having a serine, isoleucine or leucine at 240. This demifusion protein precursor also has a C-terminal arginine residue. Neither the sequence for inter- or intraconnecting peptides is found in the single copy polypeptide, so the reaction scheme can go either way. However, since N-terminal modification is desired, the multicopy fusion protein is reacted with a chemical protecting agent before it is cleaved. Since the starting material is a multicopy fusion protein, cleavage will involve reaction with a cleavage enzyme specific for the interconnecting peptide and the intraconnecting peptide which in this case are different. If the demifusion protein precursor is used, the methionine of the interconnecting peptide is first cleaved with cyanogen bromide to produce the N-terminal biological protecting group. The multicopy demifusion protein of this alternative is reacted with the chemical protecting agent before the second cleavage to release the several copies and the free N-terminal amine. Only the N-terminal  $\alpha$ -carbon is to be modified so after the cleavage step no additional cleavage or modification reactions are necessary. The modification reaction is N-terminal acetylation reaction or an acylation with a synthetic organic acylating group requiring protection of the reactive side chain groups. The final product is mastoparan having N-terminal acetyl group or an N-terminal synthetic organic acyl group. This reaction scheme can be depicted as follows:

45



35      1.    **Protection of Reactive Side Chain Groups with Chemical Protecting Agents: Amine, Hydroxyl, Carboxyl, Thiol Protection**

The purified single or multicopy fusion protein and the single or multicopy polypeptide also contain amino acids with side chains having reactive groups like  $\epsilon$ -amine, hydroxyl, carboxyl and thiol groups. In addition, one of the terminal amino acid  $\alpha$ -carbon reactive groups can also be unprotected. In order to provide for the selective modification at the N-terminal  $\alpha$ -amine and/or C-terminal  $\alpha$ -carboxyl groups, these other reactive groups are protected so that they are unavailable to react with the modifying agent.

The purified single or multicopy fusion protein and the single or multicopy polypeptide are reacted with

up to three chemical protecting agents. The protecting agent is selected by the capacity to form a protecting group at a particular type of side chain reactive group, as will be described herein. More than one protecting agent can be used depending on the different types of side chain reactive groups present in the single copy polypeptide.

Preferably, the single copy polypeptide is selected in part because it has a limited number of different side chain reactive groups to minimize the number of chemical protecting agents that are employed. For example, preferably, the single copy polypeptide is mastoparan which contains  $\epsilon$ -amine and hydroxyl groups as reactive side chain groups.

15

#### a. Amine Protection

A single or multicopy recombinant polypeptide having at least one reactive amine group is reacted with a chemical protecting agent to form an amine specific protecting group. Preferably, the single or multicopy polypeptide only contains  $\epsilon$ -amino reactive side group chains. The second protecting agent acts on  $\alpha$ -amine as well as  $\epsilon$ -amine side chain groups like those found in lysine to form a stable but reversible bond. The bond formed between the amine group and the protecting group is sufficiently stable to withstand the chemical modifying reaction conditions but also is easily reversible to allow for deprotection and regeneration of the original amine group.

Suitable chemical protecting agents that form amine protecting groups can be selected by identifying protecting groups that form a less stable bond with the unprotected groups as compared with the stability of a bond, like an amine, formed at  $\alpha$ -carboxyl of the C-terminal amino acid or the N-terminal  $\alpha$ -amine. The chemical protecting agents form bonds at unprotected amine or hydroxyl groups that are less stable than and

are different from the biological protecting group at the N- and/or C-terminal that are typically a polypeptide, peptide or an amino acid. Although not meant to limit the invention, the protecting group can be selected by identifying protecting group substituents that will stabilize the formation of a carbonium ion on the protecting group relative to the carbonium ion formed at the C-terminal  $\alpha$ -carboxyl group. Substituents containing aromatic groups, oxygen, nitrogen, unsaturated groups, aromatic acetyl groups, carbamates, and cyclic anhydrides are groups that can act to stabilize the carbonium ion on the "leaving protecting group" and act to form a stable but reversible bond with amine.

Suitable chemical protecting agents include alkyl, alkoxy or aryl carbamating agents, alkyl or aryl substituted acylating agents, and alkyl, alkoxy or aryl substituted anhydrides and aryl or unsaturated cyclic anhydrides. The order of preference of the protecting group is as follows: aryl or unsaturated cyclic anhydrides > carbamates > stabilized single acids.

Specific examples of amine protecting groups include N-trichloroacetyl, N-trifluoroacetyl, N-o-nitrophenylacetyl, N-o-nitrophenoxyacetyl, N-acetoacetyl, N-3-phenylpropionyl, N-3-(p-hydroxyphenyl)propionyl, N-2-methyl-2-(o-nitrophenoxy)propionyl, N-2-methyl-2-(o-phenylazophenoxy)propionyl, N-4-chlorobutyryl, N-o-nitrocinnamoyl, N-picolinoyl, N-(N'-acetylmethionyl), N-benzoyl, N-phthaloyl, and N-dithiasuccinoyl.

Suitable examples of carbamate protecting groups (including the amine) include methyl carbamate; N-fluorenylmethyl carbamate; 2,2,2-trichloroethyl carbamate; 2-trimethylsilylethyl carbamate; 1,1-dimethylpropynyl carbamate; 1-methyl-1-phenylethyl carbamate; 1-methyl-1-(4-biphenyl)ethyl carbamate;

- 1-dimethyl-2-haloethyl carbamate;  
 1,1-dimethyl-2-cyanoethyl carbamate; t-butyl carbamate;  
 cyclobutyl carbamate; 1-methylcyclobutyl carbamate;  
 1-adamantyl carbamate; vinyl carbamate; allyl carbamate;  
 5 cinnamyl carbamate; 8-Quinolyl carbamate;  
 N-hydroxypiperidiny carbamate;  
 4,5-diphenyl-3-oxazolin-2-one; benzyl carbamate;  
 p-nitrobenzyl carbamate; 3,4-dimethoxy-6-nitrobenzyl  
 carbamate; 2,4-dichlorobenzyl carbamate;  
 10 3-benzisoxazolylmethyl carbamate; 9-anthrylmethyl  
 carbamate; diphenylmethyl carbamate; isonicotinyl  
 carbamate; s-benzyl carbamate; and  
 N-(N'-phenylaminothiocarbonyl) derivative.

- Other amine protecting groups include N-allyl,  
 15 N-phenacyl, N-3-acetoxypentyl, quaternary ammonium salts,  
 N-methoxymethyl, N-benzyloxymethyl, N-pivaloyloxymethyl,  
 N-tetrahydropyranyl, N-2,4-dinitrophenyl, N-benzyl,  
 N-o-nitrobenzyl, N-di(p-methoxyphenyl)methyl,  
 N-triphenylmethyl, N-(p-methoxyphenyl)diphenylmethyl,  
 20 N-diphenyl-4-pyridylmethyl, N-2-picoyl-N'-oxide,  
 N,N'-isopropylidene, N-benzylidene,  
 N-p-nitrobenzylidene, N-salicylidene,  
 N-(5,5-dimethyl-3-oxo-1-cyclohexenyl), N-nitro, N-oxide,  
 N-diphenylphosphinyl, N-dimethylthiophosphinyl,  
 25 N-benzenesulfonyl, N-o-nitrobenzenesulfonyl,  
 N-2,4,6-trimethylbenzenesulfonyl, N-toulènesulfonyl,  
 N-benzylsulfonyl, N-trifluoromethylsulfonyl, and  
 N-phenacylsulfonyl.

- Especially preferred protecting agents of the  
 30 invention are maleic or citraconic anhydrides.


Typically, the amine groups can be protected by  
 formation of an amide bond by the reaction of the amine  
 groups with an anhydride as follows:



The reaction is conducted under conditions that favor the formation of a reversible, stable amide bond, preferably at the unprotected  $\alpha$ -amine group of the N-terminal amino acid and the  $\epsilon$ -amine group of lysine.

- 5 Typically, arginine and histidine are much less reactive.

Amine protection with carbamates proceeds by the reaction of the amine groups as follows:



- The reaction conditions are also chosen so that the unprotected N-terminal  $\alpha$ -amine and lysine  $\epsilon$ -amine groups are protected. Typically, arginine and histidine are relatively unreactive.

- Polypeptide amine groups can also be protected by addition of other types of groups including
- 20 N-alkylation or arylation. For example, reaction of amines with diazo compounds in the presence of boron trifluoride results in N-alkylation of the amine groups.

- The selection of reaction conditions depends upon the polypeptide amino acid composition, the type of protecting groups added and the modifying agent chosen.
- 25 Specific conditions and reagents for adding protecting groups to amine groups are described in Protective Groups in Organic Chemistry, T. Green, editor, John Wiley and Sons (1988), which is hereby incorporated by
- 30 reference.

**b. Protection of the Amino Acids Having Hydroxyl Side Chains**

- A preferred single or multicopy recombinant
- 35 polypeptide or fusion protein useful in the method of the invention has one or two different types of reactive side chain groups, including amino acids having hydroxyl side chains. For example, a polypeptide can contain  $\alpha$ -amine,  $\epsilon$ -amine and hydroxyl groups as reactive groups.

The method of the invention provides for protection of amine and hydroxyl reactive side chain groups.

The hydroxyl groups of the single or multicopy polypeptide are protected by reacting the polypeptide with the chemical protecting agent as described for amine protection. The chemical protecting agent forms a stable reversible bond at the side chain hydroxyl group in the same manner as described for amine protection. The bond formed between the hydroxyl group and the protecting group is sufficiently stable to withstand the chemical modifying reaction conditions but is also easily reversible to allow for deprotection and regeneration of the original hydroxyl group.

Suitable second protecting agents are the same as described for amine protection including alkyl, alkoxy or aryl carbonating agents, alkyl or aryl substituted acylating agents, alkyl, alkoxy or aryl substituted anhydrides, aryl or unsaturated cyclic anhydrides. The preferred protecting groups (including the hydroxyl oxygen) that form a stable but easily reversible bond are, in order of preference, aryl or unsaturated cyclic anhydrides greater than carbamates, greater than stabilized single acids.

Specific examples of the protecting groups are provided in the amine protection section herein. The highly preferred amine and hydroxyl protecting agent is maleic anhydride.

Alternatively, hydroxyl group protection can be achieved by reacting the starting material with a protecting agent that forms an ether or ester bond at the hydroxyl side chain groups. The ether or ester bonds formed are stable to the modifying conditions but are readily reversible to provide for regeneration of the original hydroxyl group.

Specific examples of hydroxyl protecting groups include the following ethers: methyl ether; methoxymethyl ether (MOM); methylthiomethyl ether (MTM);

- 2-methoxyethoxymethyl ether (MEM);  
Bis(2-chloroethoxy)methyl ether; tetrahydropyranyl ether  
(THP); tetrahydrothiopyranyl ether;  
4-methoxytetrahydropyranyl ether;  
5 4-methoxytetrahydrothiopyranyl ether; tetrahydrofuranyl  
ether; tetrahydrothiofuranyl ether; 1-ethoxyethyl ether;  
1-methyl-1-methoxyethyl ether; 1-(phenylselenyl)ethyl  
ether; t-butyl ether; allyl ether; benzyl ether;  
o-nitrobenzyl ether; triphenylmethyl ether;  
10  $\alpha$ -naphthyl diphenylmethyl ether;  
p-methoxyphenyl diphenylmethyl ether; 9-(9-phenyl-  
10-oxo)anthryl ether (Tritylone); trimethylsilyl ether  
(TMS); isopropyl dimethylsilyl ether;  
t-butyl dimethylsilyl ether (TBDMS); t-butyl diphenylsilyl  
15 ether; tribenzylsilyl ether; and triisopropylsilyl  
ether.

- Specific examples of hydroxyl protecting groups  
include the following esters: formate ester; acetate  
ester; trichloroacetate ester; phenoxyacetate ester;  
20 isobutyrate ester; pivaloate ester; adamantate ester;  
benzoate ester; 2,4,6-trimethylbenzoate (mesitoate)  
ester; methyl carbonate; 2,2,2-trichloroethyl carbonate;  
allyl carbonate; p-nitrophenyl carbonate; benzyl  
carbonate; p-nitrobenzyl carbonate; S-benzyl  
25 thiocarbonate; N-phenylcarbamate; nitrate ester; and  
2,4-dinitrophenylsulfonate ester.

### c. Protection of $\beta$ - or $\gamma$ - Carboxyl Groups

- The single copy or multicopy polypeptide or  
30 fusion protein can also have amino acids with  $\beta$ - or  
 $\gamma$ -carboxyl side chains. The  $\beta$ - or  $\gamma$ -carboxyl side  
chains can be protected with a chemical protecting agent  
that reacts with carboxyl groups to form a stable but  
reversible bond. The bond formed between the  $\beta$ -or  
35  $\gamma$ -carboxyl groups is sufficiently stable to withstand  
chemical modifying conditions at the  $\alpha$ -carboxyl group  
but is also easily reversible to allow for deprotection

and regeneration of the original  $\beta$ - or  $\gamma$ -carboxyl group. The protection conditions for protecting carboxyl groups are also selected so that the amine and/or hydroxyl protecting groups are not adversely affected.

5           Suitable protecting agents for protecting a carboxyl groups include o-nitrophenol esters, alkyl or benzyl esters, 1-hydroxybenzotriazol esters, alkylchlorocarbonates, azides and hydrazides. The especially preferred agent for the protection of  
10 carboxyl groups is o-nitrophenol.

Specific examples of carboxyl protecting groups include the following esters, amides and hydrazides: methyl ester; methoxymethyl ester; methylthiomethyl ester; tetrahydropyranyl ester; benzyloxymethyl ester;  
15 phenacyl ester; N-phthalimidomethyl ester; 2,2,2-trichloroethyl ester; 2-haloethyl ester; 2-(p-toluenesulfonyl)ethyl ester; t-butyl ester; cinnamyl ester; benzyl ester; triphenylmethyl ester; Bis(o-nitrophenyl)methyl ester; 9-anthrylmethyl ester;  
20 2-(9,10-dioxo)anthrylmethyl ester; piperonyl ester; trimethylsilyl ester; t-butyl dimethylsilyl ester; S-t-butyl ester; 2-alkyl-1,3-oxazolines; N,N-dimethylamide; N-7-nitroindoylamide; hydrazides; N-phenylhydrazide; N,N'-diisopropylhydrazide.

25           The preferred  $\alpha$ -carboxyl protecting agent can act at the  $\alpha$ - as well as the  $\beta$ - or  $\gamma$ -carboxyl groups to form active esters. Selective modification like amidation of the  $\alpha$ -carboxyl groups can be achieved by one of two methods. Protection of the  $\beta$ - or  $\alpha$ -carboxyl  
30 group can be a separate step, after the reaction of the single or multicopy polypeptide with the first protecting agent. Alternatively, protection of the  $\beta$ - or  $\alpha$ -carboxyl group can occur during the modification step.

35           In the first method, the protection of  $\beta$ - or  $\alpha$ -carboxyl groups is accomplished in a separate step, typically after the amine and hydroxyl groups have been

protected with the first chemical protecting agent. The single or multicopy peptide has an additional C-terminal amino acid such as arginine. The additional C-terminal amino acid residue acts to protect the  $\alpha$ -carboxyl group of the penultimate amino acid. The protected single or multicopy polypeptide with the C-terminal arginine residue is reacted with the second agent to add protecting groups to the  $\beta$ - or  $\gamma$ -carboxyl groups as well as the  $\alpha$ -carboxyl group of the arginine. The arginine group is removed by digestion with carboxypeptidase B leaving a single or multicopy peptide with protected  $\beta$ - or  $\gamma$ -carboxyl groups and an unprotected C-terminal  $\alpha$ -carboxyl group. The unprotected C-terminal  $\alpha$ -carboxyl group is then selectively amidated with the chemical amidating agent.

In the second method, the  $\beta$ - or  $\gamma$ - or  $\alpha$ -carboxyls are protected in the modification reaction. Selective  $\alpha$ -carboxyl modification occurs by selecting conditions that favor the more reactive  $\alpha$ -carboxyl group relative to the  $\beta$ - or  $\gamma$ -carboxyl groups. For example, when the carboxyl groups are protected by forming active esters, selective amidation occurs at the  $\alpha$ -carboxyl group by the addition of stoichiometric amounts of ammonia at a pH of a 6 to 7. While not in any way meant to limit the invention, the difference in the pKa values between the  $\alpha$ -ester and  $\beta$ - or  $\gamma$ -esters allows for the selective amidation at the  $\alpha$ -carboxyl.


#### d. Thiol Protection

A single or multicopy recombinant polypeptide having at least one reactive side chain thiol group is reacted with a chemical protecting agent to form a thiol-specific protecting group. The bond formed between the thiol group and the protecting group is sufficiently stable to withstand the chemical modifying conditions, but is also easily reversible to allow for


deprotection and regeneration of the original thiol group.

Specific examples of thiol protecting groups include S-benzyl thioether, S-p-methoxybenzyl thioether, S-p-nitrobenzyl thioether, S-4-picolyl thioether, S-2-picolyl N-oxide thioether, S-9-anthrylmethyl thioether, S-diphenylmethyl thioether, S-Di(p-methoxyphenyl)methyl thioether, S-triphenylmethyl thioether, S-2,4-Dinitrophenyl thioether, S-t-butyl thioether, S-isobutozymethyl hemithioacetal, S-2-tetrahydropyranyl hemithioacetal, S-acetamidomethyl aminothioacetal, S-cyanomethyl thioether, S-2-nitro-1-phenylethyl thioether, S-2,2-Bis(carboethoxy)ethyl thioether, S-benzoyl derivative, S-(N-ethylcarbamate), and S-ethyl disulfide. The preferred thiol protecting agent is acetic anhydride in potassium bicarbonate  $(\text{CH}_3\text{CO}_2)_2\text{O}/\text{KHCO}_3$ .

Typically, the thiol groups can be protected by formation of a thioether bond as follows:



or



The reaction is conducted under conditions that favor the formation of a reversible stable thioether bond. Typically, methionine is not reactive under these conditions.

Alternatively, thiol groups can be protected by formation of a thioester bond as follows:



The single copy or multicopy polypeptide can be transferred into an organic solvent such as

dimethylformamide, if necessary. Other reactive side chain groups are not adversely affected by these reaction conditions.

The selection of reaction conditions depends upon the single copy polypeptide amino acid composition, the type of protecting groups added, and the modifying agent chosen. Specific conditions and reagents for adding protecting groups to thiol groups are described in Protective Groups in Organic Chemistry, T. Greene, editor, John Wiley and Sons (1988), which is hereby incorporated by reference.

## 2. Cleavage of the Biological Protecting Group

The biological protecting group is cleaved to generate an unprotected N- or C-terminal  $\alpha$ -carbon reactive group. The cleavage step can take place either before or after the reaction of the starting material with the chemical protecting agents. In the preferred embodiment, cleavage occurs after protection of the side chain reactive groups with the protecting agents. The cleavage step can require more than one cleavage reagent to generate the unprotected N- or C-terminal  $\alpha$ -carbon reactive group. The unprotected C- or N-terminal  $\alpha$ -carbon reactive groups are available for modification.

The cleaving reagent is an enzyme or chemical reagent that cleaves at the recognition sequence of the inter- or intraconnecting peptide or removes intraconnecting amino acids from the N- or C-terminal end. Specific examples of the enzymes and chemical cleavage reagents specific for inter- or intraconnecting peptides are provided in Table 1. Enzymes that remove amino acid residues from the C-terminal end are carboxypeptidases and include carboxypeptidase A, carboxypeptidase B, carboxypeptidase Y, and carboxypeptidase K. Enzymes that remove residues from the N-terminal end are aminopeptidases, and include leucine aminopeptidase, aminopeptidase M, Aeromonas

aminopeptidase, X-prolyl dipeptidyl amino peptidase, as well as enzymes listed in Table 1.

A single cleavage reagent can be sufficient but multiple cleavage reagents may be necessary to provide  
5 an unprotected N- or C-terminal  $\alpha$ -carbon reaction group. The inter- or intraconnecting peptide can contain multiple cleavage sites and preferably has at least one enzymatic cleavage site and one chemical cleavage site. In site- specific cleavage, amino acid residues of the  
10 inter- or intraconnecting peptide can remain at the N- or C-terminal ends and require removal by carboxy- or aminopeptidase enzymatic digestion.

Multiple cleavage reagents and steps can also be required depending on the selection of the starting  
15 material. For example, if the starting material is a multicopy fusion protein, cleavage with a cleavage reagent specific for the inter- and intraconnecting peptide generates a mixture of single copy polypeptides. Preferably the interconnecting and intraconnecting  
20 peptide have a sequence that is recognized by the same cleavage reagent so single copy polypeptides can be generated in a single step using a single cleavage reagent. If the interconnecting and intraconnecting peptides are different, two different cleavage enzymes  
25 can be employed together or sequentially to generate the single copy polypeptides. The mixture of single copy polypeptides contain single copy polypeptides having intraconnecting peptide at the C-terminal end. If modification is to be made at the C-terminal  $\alpha$ -carboxyl  
30 group, the mixture is also cleaved with a carboxypeptidase to remove the intraconnecting peptide at the C-terminal end.

Multiple cleavage steps can be required if both the N- and C-terminal  $\alpha$ -carbon reactive groups are to be  
35 modified. For example, a recombinant single copy polypeptide protected at both the N- and C-terminal ends with biological protecting groups is sequentially

cleaved. Typically, the N-terminal biological protecting group is removed and the N-terminal  $\alpha$ -amine group is then modified. The C-terminal protecting group is then removed and the C-terminal  $\alpha$ -carboxyl group is then modified. In this case, the N- and C-terminal biological protecting groups contain different recognition sequences for cleavage reagents to allow for sequential cleavage.

In a preferred version, the recombinant multicopy fusion protein having three copies of the mastoparan polypeptide intraconnected by arginine residues and interconnected by enterokinase recognition peptide sequence to carbonic anhydrase or interconnected by a methionine glycine asparagine peptide sequence to a mini-modified carbonic anhydrase and with a C-terminal arginine is cleaved to form single copy polypeptides by sequential cleavage. The multicopy fusion protein is cleaved with enterokinase, or in the case of the mini-modified carbonic anhydrase is cleaved with CNBr to remove the carbonic anhydrase sequence, to produce respectively a multicopy polypeptide or a demifusion multicopy polypeptide. The multicopy polypeptide is then reacted with maleic anhydride which adds a protecting group to unprotected  $\epsilon$ -amino groups of lysine present in the mastoparan polypeptide. The demifusion protein is then cleaved with hydroxyl amine to remove the N-terminal biological protecting group (interconnecting peptide residue). The multicopy polypeptide or hydroxylamine treated demifusion multicopy polypeptide is then cleaved with trypsin to produce a mixture of single copy polypeptides. The protected lysine groups are not recognized and cleaved with trypsin. The mixture of single copy polypeptides contains single copy polypeptides with unprotected N-terminal  $\alpha$ -amine groups and intraconnecting peptide at the C-terminal  $\alpha$ -carboxyl group. If the C-terminal  $\alpha$ -carboxyl group is to be

modified, the unprotected N-terminal  $\alpha$ -amine is protected by reaction with a chemical protecting agent, like maleic anhydride and the C-terminal intraconnecting peptide residues are removed by cleavage with a carboxypeptidase. The side chain protected single copy polypeptide with unprotected C-terminal  $\alpha$ -carboxyl produced can then be modified.

10 **C. Selective Modification of N-Terminal  $\alpha$ -Amine and/or C-Terminal  $\alpha$ -Carboxyl Groups**

Recombinant polypeptides or peptides can be modified selectively at the N-terminal or C-terminal  $\alpha$ -carbon reactive groups by the addition of a variety of organic moieties. While not in any way meant to limit the invention, modification reactions at the C-terminal  $\alpha$ -carboxyl or N-terminal  $\alpha$ -amine groups are those that proceed by nucleophilic substitution. Nucleophilic substitutions are described in Advanced Organic Chemistry, in Chapter 10, 3rd ed., John Wiley and Sons, editor, NY (J. March 1984), which is hereby incorporated by reference. The bonds formed at the N- and/or C-terminal  $\alpha$ -carbon reactive groups are stable and generally irreversible under the deprotection conditions employed to regenerate the side chain groups.

25 Polypeptides can be sequentially modified at the N- and C-terminal  $\alpha$ -carbon reactive group by the same or different modifications.

Specific examples include addition to or replacement of terminal amino acids with a D-amino acid, D-amino acid containing peptide, L-amino acid peptide, or an amino acid analogue or derivative at one or both of the terminal ends of the recombinant polypeptide by formation of an amide bond. Another modification is the conversion of an N-terminal glutamic acid or glutamine to a pyroglutamyl residue. The preferred modification of the method of the invention is the selective C-terminal  $\alpha$ -carboxyl amidation reaction or the selected

N-terminal  $\alpha$ -amine reaction with a synthetic organic group.

The modification made to the N-terminal and/or C-terminal  $\alpha$ -carbon reactive group can be selected according to several factors. Factors to be considered in selecting the terminal modifications are the amino acid sequence of the single copy polypeptide, the size of the single copy polypeptide, the change in the biological activity of the single copy polypeptide, how the modified single copy polypeptide is going to be used, and prevention of racemization at the modified N- and/or C-terminal  $\alpha$ -carbon.

The amino acid sequence of the single copy polypeptide preferably has about one or two different reactive side chain groups. For example, a polypeptide having an  $\epsilon$ -amine and hydroxyl side chain groups can be protected in a single step using an amine protecting agent as described previously. The modifications, conditions and agent are chosen so that the  $\epsilon$ -amine and hydroxyl groups are not deprotected or otherwise adversely affected during the modification reaction. In contrast, a single copy polypeptide with both  $\epsilon$ -amine, hydroxyl,  $\beta$ - or  $\gamma$ -carboxyl, and thiol groups can require reaction with three different protecting agents to provide for side chain protection of the  $\epsilon$ -amine and hydroxyl groups,  $\beta$ - or  $\gamma$ -carboxyl groups, and thiol groups. The modification conditions and reactions are selected so that the side chain protecting groups remain intact and are not adversely affected.

Conditions that lead to deprotection of the amine, carboxyl and thiol protecting groups are described in Protecting Groups in Organic Synthesis, T. Green, editor, John Wiley and Sons (1988). These conditions should be avoided during the modification process and, thus, the modification reaction conditions should be chosen to avoid or prevent deprotection of these side chain reactive groups.

The size of the single copy polypeptide is preferably about 10-50 amino acids. While the selective modification methods of the invention can be conducted on larger polypeptides, reaction conditions for adding protecting groups and modifying groups are selected so as not to cause irreversible denaturation of the polypeptide. Polypeptides with greater than 50 amino acids are protected and modified in aqueous solutions of a pH of about 2-10 and a temperature of less than about 50°C.

Modifications to the polypeptide can change the biological activity of the polypeptide. For example, C-terminal amidation of many small peptides, like mastoparan or the human gastrin releasing peptide, enhances the biological activity of these peptides. Moreover, addition of peptide sequences of D or L-amino acids can provide for targeting of the polypeptide to a specific cell type, decreasing the rate of breakdown and clearance of the peptide, increasing the biological potency and adding other biological activities to the polypeptide. Addition of D-amino acids or peptides or derivatives of amino acids can also result in the formation of antagonists. The choice of modification can be made upon the desired change of the biological activity of the peptide.

The fourth factor to consider in selecting modifying reactions and conditions is how the modified product is going to be used. If the polypeptide is to be used in vivo, the modification selected can be one that enhances, targets, expands, or inhibits the biological activity of the polypeptide. If the polypeptide is being modified for use in a diagnostic test, the impact of the modification on the structure of the polypeptide rather than the biological activity is examined. For use in diagnostic tests, the modified polypeptide is still specifically recognized by antibodies or by specific binding to a target molecule.


The fifth factor to consider in choosing the modification reaction and conditions is to prevent formation of a racemic mixture of the modified single copy polypeptides. Some types of modification reactions are known to result in racemic mixtures and, thus, are not suitable for the method of the present invention.

Specific examples of modification reactions and conditions follow.

1. Selective Amidation of the Carboxy-Terminal Amino Acid

The protected single copy polypeptide having unprotected C-terminal  $\alpha$ -carboxyl group is reacted with a chemical amidating agent by standard methods, as described in Bodanszky, Peptide Chemistry: A Practical Textbook, Springer-Verlag, publisher (1988), which is hereby incorporated by reference. Suitable chemical amidating agents include 1-ethyl-3-(3-dimethylaminopropyl) ethyl carbodiimide hydrochloride and ammonia, water soluble carbodiimides and ammonia, dicyclohexyl carbodiimide and ammonia, acid chlorides and ammonia, azides and ammonia, mixed anhydrides and ammonia, methanolic HCl and ammonia, o-nitrophenyl esters and ammonia and esters of 1-hydroxybenzotrazole and ammonia.

Typically, the protected polypeptide is reacted with a chemical amidating agent like carbodiimide and o-nitrophenol to form activated esters as follows:



The amidation occurs upon addition of ammonia or a source of ammonia to the active ester. Other carboxyl or acidic side chains present in the polypeptide, if not already also protected, form active esters. In order to provide for a selective  $\alpha$ -carboxyl C-terminal amidation, reaction conditions are chosen to favor amidation at the



more reactive  $\alpha$ -carboxyl in contrast to the  $\beta$ - or  $\gamma$ -carboxyl side chains. For example, addition of a stoichiometric amount of ammonia at a pH of about 6 favors the formation of the amide at the  $\alpha$ -carboxyl group. Carboxyl activating and amidation conditions are also such that deprotection of the amine hydroxyl groups does not occur.

An alternative method of amidation is to react the unprotected C-terminal  $\alpha$ -carboxyl group with the photonucleophile o-nitrophenol-glycineamide. The photonucleophile acts to convert the carboxyl group to the amide.

The selection of reaction conditions depends upon the amino acid composition of the polypeptide, the type of protecting group utilized, and the chemical amidating agent chosen. For example, if the polypeptide does not contain  $\beta$ - or  $\gamma$ -carboxyl groups, the utilization of conditions favoring  $\alpha$ -carboxyl amidation is not necessary.


The preferred side chain protected mastoparan polypeptide is reacted with 1-ethyl-3-(3-dimethylaminopropyl) ethyl carbodiimide hydrochloride in the presence of excess  $\text{NH}_4\text{OH}$  to form a C-terminal amidated protected mastoparan polypeptide. Since mastoparan does not contain aspartic or glutamic acid, reaction conditions are not adjusted to favor amidation of the  $\alpha$ -carboxyl group. The C-terminal amidated protected polypeptide is then deprotected and purified.

## 2. Modification of N-terminal and C-terminal Amino Acid With D-amino Acids or Peptides, L-Amino Acid Peptides, and Amino Acid Derivatives

A D-amino acid, L-amino acid, an amino acid derivative, or peptides containing a combination thereof can be added to the N-terminal and/or C-terminal  $\alpha$ -carbon reactive group of the protected single copy polypeptide by transamidation or by segment condensation reaction. Alternatively, the D-amino acid, L-amino

acid, amino acid derivative or peptides containing a mixture thereof can replace the N-terminal or C-terminal amino acid or amino acids of a portion of a side chain protected recombinant single copy polypeptide.

- 5 Typically, a D-amino acid, L-amino acid, amino acid derivative, or peptide can be added by well known solution or solid phase peptide synthesis, as described in Solid Phase Peptide Synthesis, 2nd Edition, J.M. Steward and J.D. Young, editors, Pierce Chemical Co.,  
 10 Rockford, IL (1984), which is incorporated herein by reference. One example of such a reaction is adding a urethane blocked amino acid to the free N-terminal  $\alpha$ -amine of the side chain protected single copy polypeptide in the presence of carbodiimide, mixed  
 15 anhydrides or active esters. The reaction scheme is represented as follows:




- 25 An alternative synthesis is the segment condensation procedure, which is preferably used when small peptides are coupled to the N-terminal  $\alpha$ -amine groups as described by F. Finn et al., in The Proteins, 3rd ed., Neurath and Hill, editors, Academic Press, NY,  
 30 Vol. 2, pp. 105-253 (1976), which is hereby incorporated by reference.

- Replacement of the N-terminal amino acid(s) can be accomplished by removing the N-terminal amino acid or amino acids by cleavage with a chemical or enzymatic  
 35 cleavage reagent like those provided in Table 1 or with an amino or carboxypeptidase. Alternatively, the recombinantly produced single copy polypeptide can be produced so that gene sequence lacks the codons for the N-terminal or C-terminal amino acid or amino acids. The  
 40 protected single copy polypeptide preferably lacking up

to about 10 N-terminal amino acids can be modified by the addition of a D-amino acid, L-amino acid, amino acid derivative, or peptide containing a mixture thereof as described above.

5 A specific example includes replacement of the two N-terminal amino acids of ovine  $\beta$ -endorphin with a dipeptide Tyr-D-Ala. The naturally occurring ovine  $\beta$ -endorphin has 31 amino acids. The starting material for the recombinantly produced peptide is a multicopy  
10 polypeptide fusion protein containing multicopies of a truncated  $\beta$ -endorphin (amino acids 3-31) intraconnected by arginine.



#### Key

35 BP-Arg-B<sub>3-31</sub>-Arg-B<sub>3-31</sub>-Arg-B<sub>3-31</sub>-Arg = multicopy fusion protein  
composed of binding protein  
40 (BP) interconnected by Arg  
to multiple copies of  
truncated  $\beta$ -endorphin (B<sub>3-31</sub>)  
intraconnected by arginine

NH<sub>2</sub>-B<sub>3-31</sub>-Arg = single copy truncated ovine  
45  $\beta$ -endorphin with C-terminal  
arginine and unprotected  
N-terminal  $\alpha$ -amine

Fmoc-Tyr-D-Ala = dipeptide protected at  
N-terminal with Fmoc

65

(9-fluorenylmethyloxycarbon-  
yl)

5 Fmoc-Tyr-D-Ala-B<sub>3-31</sub>-Arg = N-terminal modified  
protected  $\beta$ -endorphin

Tyr-D-Ala-B<sub>3-31</sub> = N-terminally modified  
 $\beta$ -endorphin

10 Specific examples of the types of modifications  
made to biologically active peptides include addition of  
L-N-(2-oxopiperidine-6-ylcarbonyl)-L-histidyl-L-  
thiazolidine-4-carboxamide to thyroliberin (TRF),  
3-methylhistidine to TRF, modified C-terminal  
15 des-Gly<sup>10</sup>-Pro<sup>9</sup>-N-ethylamide to leutinizing releasing  
factor (LRF), modified N-terminal of LRF with Ac-D-Phe<sup>1</sup>  
and/or PCl-D-Phe<sup>2</sup>, N-terminal pyroglutamyl residue to  
litorin, D-alanine at the 2-position of enkephalin,  
C-terminal modification adding methioninol sulfoxide at  
20 the C-terminal of enkephalin, and  $\alpha$  and  $\gamma$  endorphin  
amides. Other analogs of biologically active peptides  
are described in Kirk-Othmer Chemical Encyclopedia,  
12:603-617, which is hereby incorporated by reference.  
The preferred modification is the additional of a  
25 D-amino acid at the C-terminal or N-terminal end of the  
protected single copy polypeptide.


Specific examples of derivatives of amino acids  
that can be added to or replace terminal amino acids  
include pyroglutamyl residues, homoserine,  
30 hydroxyproline, 3-methylhistidine, hydroxylysine,  
desmosine, N-methylglycine, N-methylisoleucine, and  
N-methylvaline.

### 3. Formation of N-Terminal Acetyl Groups



35 Naturally occurring polypeptides and analogues  
can have N-terminal acetyl groups or N-terminal  
oligopeptide prefix sequence or N-terminal synthetic  
organic moieties. The modification reaction providing  
for N-terminal acetyl groups or N-terminal oligopeptide  
40 prefix sequence or N-terminal synthetic organic moieties

involves reaction of a protected single copy polypeptide with an unprotected N-terminal  $\alpha$ -amine group with acetic anhydride or oligopeptide prefix or synthetic organic moiety as follows:

5



10



15 An example of an analogue that has an acetylated N-terminal amino acid is an LRF antagonist.

#### D. Deprotection

20 The side chain protected modified polypeptide is then deprotected using a variety of conditions depending upon the particular protecting group involved. Deprotection involves removal of the protecting group and regenerating the original reactive group without undesirable side reactions. Deprotection conditions do not adversely affect the N- and/or C-terminal  
25 modification.

The deprotection conditions chosen will depend on the type of protecting group. For example, amide and carbamate protecting groups can be removed by incubation under acidic condition of a pH ranging from about 1-4.  
30 Other conditions allowing for the removal of the amine and hydroxyl protecting groups without undesirable side reactions are described in Protective Groups in Organic Chemistry, cited *supra*.

35 Specific examples of the cleavage of the amine and hydroxyl protecting groups include the following reactions:

Cleavage of carbamates:

- 5            1)  $\text{RNHCOO}(\text{CH}_3)_3 \text{ COOC}(\text{CH}_3)_3 \xrightarrow[25^\circ\text{C } 1 \text{ hr.}]{\text{CF}_3\text{COOH/PhSH}} \text{RNH}_2$
- 10           2)  $\text{RNH-N-9-fluorenyl} \xrightarrow[10 \text{ min.}]{\text{piperidine } 25^\circ\text{C}} \text{RNH}_2$
- 15           3)  $\text{RNHCOCH} = \text{CHCOOH} \xrightarrow[2 \text{ hrs.}]{\text{pH } 2-3} \text{RNH}_2$

Carboxyl protecting groups can be removed by incubation at a high pH of about 8-11. Other conditions for removal of carboxyl protecting groups without  
 20 undesirable side reactions are described in Protective Groups in Organic Chemistry, cited supra. Specific examples of the cleavage of carboxyl protecting groups include the following reactions:


- 25            $\text{RCOOOCH}_2\text{SCH}_3 \xrightarrow[25^\circ\text{C, } 15 \text{ min.}]{\text{CF}_3\text{COOH}} \text{RCHOOH, } 80-90\%$
- 30            $\text{ArCOO-t-Bu} \xrightarrow[100^\circ\text{C, } 5 \text{ hr., } 94\%]{\text{KOH/18-crown-6, PhMe}} \text{ArCOOH}$

35           Thiol protecting groups can be removed in the presence of Na and  $\text{NH}_3$ . Other conditions for removal of thiol protecting groups are described in Protective Groups in Organic Chemistry, cited supra.

Specific examples of the cleavage of thiol  
 40 protecting groups include the following reactions:

- 45           1)  $\text{CysSCH}_2\text{C}_6\text{H}_5 \xrightarrow[10 \text{ min.}]{\text{Na/NH}_3} \text{CysSH}$

68



5

In addition, the modified side chain protected polypeptide can also have the intraconnecting peptide residues at the C- or N-terminal end. If the intraconnecting residues were not removed at an earlier point in the reaction scheme, they can be digested and removed with a cleavage enzyme, like a carboxy or aminopeptidase.

If the side chain protected single copy polypeptide has more than one type of protecting group present, like for example an amine protecting group and carboxyl protecting group, deprotection can be conducted so that the protecting groups are removed sequentially. For example, the amine and hydroxyl protecting groups can be removed by incubation at a pH of about 2 for 2 hours. Then the carboxyl protecting groups can be removed by incubating at a pH of about 8-11 for 2 hours. Other combinations of deprotection conditions can be utilized to remove protecting groups from the reactive side chains to regenerate the original reactive group.

After deprotection, the final product is a single copy polypeptide with a modified C- and/or N-terminal amino acid. The final product can be purified by standard methods including size exclusion, ion exchange, or affinity chromatography. In a preferred version, a small peptide like mastoparan can be purified by size exclusion column or HPLC chromatography.

The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications can be made while remaining within the spirit and scope of the invention.

EXAMPLE 1

**Formation of a C-Terminal  $\alpha$ -Amide Polypeptide  
from a Recombinant Multicopy Fusion Protein  
Having C-terminal Arginine Groups**

5           An expression vector that has a recombinant  
gene encoding a multicopy fusion protein is formed by  
standard recombinant DNA methodologies. Briefly, the  
gene for human carbonic anhydrase is modified by removal  
10 of the nucleotide sequence for the three C-terminal  
amino acids. Alternatively, the gene for mini-modified  
human carbonic anhydrase is modified by conversion of  
methionine 240 to leucine or serine and removal of the  
nucleotide sequence for the three C-terminal amino  
15 acids. The gene encoding a multicopy polypeptide  
containing three copies of a mastoparan polypeptide  
intraconnected by arginine residues and having a C-  
terminal arginine is synthesized by automated  
techniques. The automated techniques are described  
20 generally by S. Beaucage et al., Tetra. Letters, 221:859  
(1981) which is hereby incorporated by reference. The  
synthesis of the multicopy mastoparan polypeptide with  
C-terminal arginine (45 amino acids) is conducted using  
optimal codon usage for E. coli and results in a  
25 multicopy polypeptide having useful restriction  
endonuclease sites. The DNA sequence for the  
interconnecting peptide containing enterokinase  
recognition sequence (Val-Asp-Asp-Asp-Lys) (SEQ ID NO:8)  
is synthesized by the automated methods as described  
30 above. Alternatively, the interconnecting peptide DNA  
sequence can be a methionine glycine asparagine glycine  
sequence for use with the mini-modified human carbonic  
anhydrase. This gene can be synthesized by the  
automated methods as described above.

35           The gene for human carbonic anhydrase is  
inserted in a plasmid downstream from a T7 promoter by  
standard methods generally known in the art and  
described by Sambrook et al., cited supra. The DNA  
sequence for the interconnecting peptide is inserted

downstream from the carbonic anhydrase gene. The gene encoding a multiple copy of the mastoparan polypeptide is inserted immediately downstream from the sequence for the interconnecting peptide.

5           Typically DNA sequences are inserted by restriction endonuclease digestion and ligation as described herein. A 0.5 to 2 mg sample of plasmid DNA is digested in 20 ml of a 1X restriction buffer with 1 to 20 units of restriction enzyme. The reaction mix is  
10 incubated for 1 to 16 hours at the temperature recommended by the enzyme supplier. The linearized vector can then be dephosphorylated with calf intestinal phosphatase or bacterial alkaline phosphatase under conditions known to those with skill in the art, e.g.  
15 suggested by the supplier. The DNA is then further purified by standard procedures (See Sambrook et al., cited supra) which usually involve a phenyl extraction and ethanol precipitation.

          The DNA segment to be inserted is then mixed in  
20 a 3 to 5 fold (for large fragments) or 20 to 30 fold (for short oligonucleotides) molar excess precut cloning vector. The ligation is performed in a 1X ligation buffer (20 mm tris pH 7.6, 10mm magnesium chloride, 0.4mm  $\beta$ -mercaptoethanol, 0.4 to 1m ATP), in the presence  
25 of T4 DNA ligase at 16°C for 16 hours. The same procedure is repeated successively to add DNA segments successively and the restriction endonucleases are chosen to selectively place the newly inserted DNA segments. An aliquot of a reformed vector is then used  
30 to transform competent E. coli cells by calcium chloride precipitation and selected for recombinant plasmids.

          Bacteria are transformed with the plasmid DNA. Luria Broth is inoculated with a bacterial culture and the cells are grown with agitation at optimum  
35 temperature to a density of about  $10^5$  to  $10^7$  cells per ml. The culture is chilled to about 0°C, centrifuged and the cells are collected. The cells are then

resuspended in an ice cold sterile solution of 50mm or calcium chloride and 10mm tris chloride (pH 8.0). The centrifuge and resuspension step is repeated one more time. The results of the concentrated suspension of  
5 treated cells are ready to accept the new vector. Typically the new vector contains a selective marker or reporter gene. Selective marker genes generally encode antibiotic resistance.

For maximum transformation efficiency the  
10 bacterial culture preferably is in logarithmic phase of growth; the cell density preferably is low at the time of treatment with calcium chloride; and the treated cells are preferably maintained at 40°C for 12 to 24 hours. To take up the vector an aliquot of the ligation  
15 reaction is added to the suspension of treated cells. The combination is mixed and stored on ice for a short time. Up to 40 nanograms of DNA (dissolved in up to 100 microliters of ligation buffer or TE) can be used for each transformation. Next, the transformed cells and  
20 culture tubes are transferred to a 40°C water bath for 2 minutes. An aliquot of luria broth is added to each tube and the cells incubated at 37°C for about 30 minutes (tetracycline selection) or 1 hour (ampicillin or kanamycin selection). This period of time allows the  
25 bacteria to recover and to begin to express antibiotic resistance. The cells are spread onto selective media and incubated at optimum temperature. Colonies will appear overnight (adapted from Sambrook et al., cited supra.

30 Transformed E. coli are selected through the use of plates containing the appropriate antibiotic (i.e., the one to which resistance is conferred by the introduced plasmid). Typical final concentrations are ampicillin at a 100 micrograms per ml, chlorophenicol at  
35 10 micrograms per ml, kanamycin at 50 micrograms per ml, streptomycin at 25 micrograms per ml, tetracycline at 15 micrograms per ml. When using E. coli bl21 (DE3) plys

as the host, transformants are plated out on a medium containing both ampicillin and chlorophenicol at the above concentrations.

In a preferred embodiment the method for  
5 culturing transformed cells can be practiced as described in Sambrook et al., cited supra. Briefly, the method entails transferring of single transformed and selected bacterial colony to a small volume (3 to 5 ml) of bacterial growth medium (such as luria broth)  
10 containing an appropriate antibiotic. The culture is incubated at 37°C (or other appropriate temperature) and scaled up to large volumes.

Cells are lysed with sonication in 830 ml of 50mm Tris-HCl(pH 7.9) - 0.5mm EDTA containing 100mm  
15 sodium chloride with 10 micrograms per ml of DNASE I. Lysozyme (30 milligrams) is added and the lysate is incubated overnight to disrupt the cell fragments.

To purify recombinant protein from insoluble granules, the lysate is then centrifuged, incubated with  
20 sodium deoxycholate, and washed several times. The cell lysate is then frozen and thawed. The cell lysate is further purified by ultrafiltration and DEAE column chromatography. The partially purified fusion protein is then further purified on an affinity column  
25 containing sulfanilamide. The partially purified cell lysate is pumped through a column of sulfanilamide-sepharose prepared by conventional methods. The bound protein is washed with 0.5M Tris-sulfate-1M-sodium sulfate (pH 7.5) to remove other materials. The bound  
30 multicopy fusion protein containing carbonic anhydrase is eluted with 0.2M potassium thiocyanate and 0.5M-Tris-sulfate (pH 7.5).

The purified multicopy fusion protein is digested with bovine enterokinase in 10mm tris buffer  
35 (pH = 8.0) at 37°C for 15 hours. The enterokinase cleaves at the Asp<sub>4</sub>Lys interconnecting peptide to form free carbonic anhydrase enzyme and a multicopy fusion

protein with a free  $\alpha$ -amine group and a C-terminal arginine group. The multicopy peptide is purified from the carbonic anhydrase by ultrafiltration.

Alternatively, the purified multicopy demifusion protein precursor is treated with cyanogen bromide in tris buffer (pH=8.0) to cleave the carbonic anhydrase sequence. The multicopy demifusion peptide is purified from the carbonic anhydrase residue by ultrafiltration.

The  $\alpha$ -amine,  $\epsilon$ -amine groups and hydroxyl groups present in the multicopy polypeptide are protected by reaction of the polypeptide with an amine protecting group like maleic anhydride. If the multicopy demifusion protein is used, the  $\alpha$ -amine is already protected by a biological protecting group and the  $\epsilon$ -hydroxyl groups present in the multicopy demifusion polypeptide are protected as described above. The maleic anhydride reacts with amines and forms acidic amide protecting groups in the presence of 5M GuHCl (pH 8 to 8.5). This reaction is followed by a buffer exchange by 1K ultrafiltration.

If the multicopy polypeptide contains carboxyl groups, the  $\beta$ - or  $\gamma$ -carboxyl groups are protected using an activated alcohol like methanol or ethanol. The multicopy polypeptide or the multicopy demifusion polypeptide is then cleaved with trypsin. The trypsin cleaves only at the intraconnecting arginine residues and not at the amine protected lysine residues. The trypsin digestion results in the formation of single copy polypeptides, some of which have free N-terminal amine groups or if the multicopy demifusion polypeptide is used, all of which have free N-terminal amine groups.

The single copy polypeptides are then digested with carboxypeptidase B. The carboxypeptidase B cleaves arginine residues from the C-terminal. If the C-terminal arginine residues are protected at the  $\alpha$ -carboxyl group the carboxypeptidase cleaves the ester-protecting group as well as removing the arginine.

The mixture of single copy polypeptides, some ... having free  $\alpha$ -amine groups is treated with maleic anhydride again to protect the free amine groups generated upon cleavage with trypsin. The fully  
5 protected single copy polypeptides are then exchanged into a mixture of dimethylformamide and methylene chloride.

The protected polypeptide has protected N-terminal  $\alpha$ -amine and an unprotected C-terminal  $\alpha$ -  
10 carboxyl group generated upon cleavage of the C-terminal arginine. The protected polypeptide is reacted with dicyclohexylcarbodiimide and o-nitrophenol to produce an active ester at the C-terminal  $\alpha$ -carboxyl group. The activated protected polypeptide is then transferred to  
15 an aqueous solution ammonia to form the amine protected C-terminal  $\alpha$ -amide polypeptide.

The protected  $\alpha$ -amidated polypeptide amine and hydroxyl groups are deprotected by treatment at a pH of about 2.0 for 2 hours at 20°C. The carboxyl groups are  
20 deprotected by alkaline treatment at a pH of about 8 to 10. The deprotected C-terminal  $\alpha$ -amide polypeptide is purified by size exclusion chromatography.

## **EXAMPLE 2**

### **25      Formation of C-terminal $\alpha$ -Amide Polypeptide from a Recombinant Multicopy Protein**

Recombinant multicopy protein is formed as described in Example 1. The recombinant multicopy protein has multiple copies of the single copy  
30 polypeptide connected with an intraconnecting peptide. The recombinant multicopy polypeptide contains three copies of the myosin light chain kinase inhibitor intraconnected with glutamic acid. The sequence of the myosin light chain kinase inhibitor is Lys-Arg-Arg-Trp-  
35 Lys-Lys-Asn-Phe-Ala-Val (SEQ ID NO:9). The DNA sequence encoding the multicopy protein is synthesized by automated methods, and cloned downstream from the T7

promoter in an expression vector prepared as described in Example 1.

The recombinant multicopy protein is expressed in transformed E. coli having a recombinant expression vector prepared as described in Example 1. The recombinant multicopy protein is purified from transformed cell lysates by affinity chromatography utilizing an immobilized monoclonal antibody specific for myosin light chain kinase inhibitor.

The multicopy polypeptide is then cleaved with Staphylococcus aureus V8 cleavage enzyme at the glutamic acid to form a mixture of multiple units of single copy polypeptides. The mixture of single copy polypeptides also contains polypeptides having unprotected  $\alpha$ -amine groups and side chain amine groups generated by the enzyme cleavage of the intraconnecting peptide. These unprotected  $\alpha$ -amine groups are protected by reaction with maleic anhydride to form a fully protected single copy peptide having C-terminal glutamic acid residues. The C-terminal glutamic acid residues are removed by carboxypeptidase at pH 4.5.

The removal of the C-terminal glutamic acid and protection of  $\alpha$ - and  $\epsilon$ -amine groups can be conducted in either order. The fully protected single copy polypeptide is amidated by a reaction with dicyclohexylcarbodiimide in DMF/DCM followed by reaction with ammonium hydroxide. Amidation occurs selectively at the  $\alpha$ -carboxyl C-terminal amino acid to form a protected C-terminal  $\alpha$ -amide.

The protected C-terminal  $\alpha$ -amide of myosin light chain kinase inhibitor is deprotected at pH 2 for about 2 hours. The  $\alpha$ -amidated myosin light chain kinase inhibitor is purified by HPLC size exclusion chromatography.

**EXAMPLE 3****Formation of C-terminal  $\alpha$ -Amide Polypeptide  
from a Recombinant Single Copy Fusion Protein**

5           The recombinant single copy fusion protein is  
formed as described in Example 1 accept that carbonic  
anhydrase is connected by an arginine to a single copy  
of a polypeptide wound healing factor. The sequence of  
the wound healing factor is Ala-Phe-Ser-Lys-Ala-Phe-Ser-  
10 Lys-Ala-Phe-Ser-Lys-Ala-Phe-Ser-Lys-Ala-Phe-Ser-Lys (SEQ  
ID NO:1). The gene encoding the peptide is produced by  
automated techniques as described in Example 1 and  
combined with the gene for the binding protein and the  
interconnecting peptide in an expression vector as  
15 described in Example 1. The single copy fusion protein  
is expressed and purified as described in Example 1.

          The recombinantly produced fusion protein is  
cleaved at the arginine interconnecting peptide with  
clostripain to form a single copy polypeptide with an  
20 unprotected  $\alpha$ -amine group at the N-terminal.

          The single copy polypeptide is reacted with  
maleic anhydride in 5M GuHCl (pH 8 to 8.5) to form a  
protected single copy polypeptide.

          The protected single copy polypeptide is  
25 reacted with water soluble carbodiimide in an excess of  
ammonium hydroxide as an amidating agent to form a  
protected C-terminal  $\alpha$ -amide polypeptide.

          The protected C-terminal  $\alpha$ -amide polypeptide is  
deprotected at pH 2 for about 2 hours, and the C-  
30 terminal  $\alpha$ -amidated wound healing factor is purified by  
HPLC size exclusion chromatography.

**EXAMPLE 4****Selective Modification of the N- and C-terminal  
Amino Acid  $\alpha$ -Carbon Reactive Groups of a  
Recombinant Polypeptide**

35

          The recombinant single copy fusion protein is  
formed as described in Example 3. The single copy

fusion protein contains carbonic anhydrase as the binding protein (N-terminal  $\alpha$ -amine protecting group) interconnected via the thrombin recognition peptide (Arg-Gly-Pro-Arg) (SEQ ID NO:4) to the wound healing factor with an additional C-terminal arginine residue (C-terminal  $\alpha$ -carboxyl protecting group). The single copy polypeptide is protected at both the N- and C-terminal  $\alpha$ -carbon reactive groups. The recombinant single copy fusion protein is expressed in a transformed host and purified as described in Example 1.

The recombinant single copy fusion protein is reacted with maleic anhydride in 5M GuHCl(8 to 8.5) to form a protected single copy polypeptide. The maleic anhydride protects the side chain groups of serine and lysine.

The protected single copy fusion protein is then cleaved with thrombin. The thrombin cleaves at the interconnecting peptide to form a protected polypeptide having an unprotected N-terminal  $\alpha$ -amine group.

The protected polypeptide with the unprotected N-terminal  $\alpha$ -amine group is reacted with a first modifying agent - a pyroglutymal amino acid, in the presence of carbodiimide to form an amide bond between the N-terminal amino acid and a pyroglutymal residue. The reaction is conducted in an organic solvent like DMF to provide solubility of pyroglutymal and carbodiimide. The protected single copy polypeptide is now modified selectively at the N-terminal  $\alpha$ -amine reactive group.

The C-terminal arginine is then cleaved off with carboxypeptidase B to form a protected single copy polypeptide modified at the N-terminal  $\alpha$ -amine and having an unprotected C-terminal  $\alpha$ -carboxyl group. The unprotected C-terminal  $\alpha$ -carboxyl group is reacted with a water soluble carbodiimide and excess ammonium hydroxide to form a protected single copy polypeptide with a N-terminal  $\alpha$ -amine modified and C-terminal  $\alpha$ -carboxyl amide.

The protected single copy polypeptide with the C-terminal  $\alpha$ -amide and the N-terminal  $\alpha$ -amine pyroglutymal residue is deprotected in an acidic solution at a pH 2 for two hours. After deprotection, the final product is a wound healing factor peptide modified at the C-terminal  $\alpha$ -carboxyl by amidation, and modified at the N-terminal  $\alpha$ -amine with an additional pyroglutymal residue.

10

**EXAMPLE 5****Replacement of N-terminal Amino Acids of Bradykinin Derived from A Multicopy Fusion Protein**

The starting material is a multicopy fusion protein containing three copies of a truncated bradykinin peptide interconnected by Asn-Gly to a mini-modified carbonic anhydrase (Leu Ser 240). The mini-modified carbonic anhydrase gene is obtained and subcloned into the base vector downstream of a T7 promoter as described in Example 1. The gene for the multicopy polypeptide is synthesized by automated synthesis and includes three copies of the coding sequence for amino acid residues 4-9 of bradykinin tandemly linked with the coding sequence for Met Gly Asn interconnected to the N-terminal of the multicopy polypeptide as follows (SEQ ID NO:10):

Met-Gly-Asn-Gly-Phe-Ser-Pro-Phe-Arg-  
Gly-Phe-Ser-Pro-Phe-Arg-Gly-Phe-Ser-  
Pro-Phe-Arg

The Met-Gly-Asn serves as interconnecting peptide cleavable by cyanogen bromide and hydroxylamine. No intraconnecting peptide is necessary as trypsin will cleave at the C-terminal arginine. The gene encoding the multicopy polypeptide with interconnecting peptide is cloned downstream from the mini-modified carbonic anhydrase as described in Example 1. The vector containing the gene sequence for the recombinant multicopy fusion protein is introduced into a host organism as described in Example 1. The recombinant

multicopy fusion protein is expressed and purified, as described in Example 1.

The purified multicopy fusion protein is cleaved with 1M cyanogen bromide, pH 8 at 37°C to remove the carbonic anhydrase fragment and form a biological protected demifusion protein. After capture of the cleaved carbonic anhydrase with a sulfanilamide column, the serine hydroxyl groups of the separated demifusion protein can be protected by reaction with maleic anhydride. The biological protecting group can be cleaved with 2M hydroxylamine in 5M GuHCl, pH 8.0 at 37°C to form a multicopy polypeptide. The multicopy polypeptide is cleaved with trypsin to form a truncated single copy polypeptide with unprotected N-terminal  $\alpha$ -amine reactive groups.

The first three amino acids of bradykinin containing a hydroxyproline residue (Hyp) are synthesized by solid phase or solution chemistry. The Arg-Pro-Hyp peptide is synthesized by first forming the 9-fluorenyl methyloxycarbonyl hydroxyproline (FMOC) o-benzylether derivative (FMOC derivative). The FMOC hydroxyproline derivative is reacted with the hydroxide resin to produce FMOC-Hyp-resin. The FMOC is removed with piperidine and DCM (dichloromethane). A dicyclohexylcarbodiimide activated FMOC-proline derivative is then reacted with the resin bound  $\text{NH}_2$ -Hyp. The cycle is repeated for FMOC-Arg-(methoxy-2,3,6-trimethylbenzine sulfonyl). The protected peptide is then cleaved from the resin with 25% trifluoroacetic acid in dichloromethane.

The protected N-terminal tripeptide: Arg-(methoxy-2,3,6 trimethylbenzine sulfonyl)-Pro-Hyp-COOH is activated with dicyclohexyl carbodiimide in dichloromethane and dimethylformamide. The activated peptide is then reacted with a twofold excess of recombinantly produced truncated bradykinin (amino acid residues 4-9) to produce Hyp-3-bradykinin. Excess

recombinantly produced bradykinin (amino acids 4-9) can be recovered and used again.

#### EXAMPLE 6

5                   **Formation of N and C-Terminally Modified  
                    Growth Hormone Releasing Factor (GRF)  
                    Derived From a Multicopy Fusion Protein**

                    The starting material is a multicopy fusion  
10 protein containing two copies of growth hormone  
                    releasing factor intraconnected to form a multicopy  
                    polypeptide connected to carbonic anhydrase. The  
                    interconnecting peptide and intraconnecting peptide are  
                    the same and contain a recognition sequence for an  
15 enzymatic cleavage reagent and a recognition sequence  
                    for a chemical cleavage reagent. The sequence (SEQ ID  
                    NO:11) of the inter- and intraconnecting peptide is:



                    A = hydroxylamine cleavage site  
                    B = thrombin cleavage site

                    The gene sequence for the carbonic anhydrase is  
25 obtained and subcloned into the base vector downstream  
                    of the T7 promoter, as described in Example 1. The gene  
                    sequence for growth releasing factor containing the  
                    inter- or intraconnecting peptide at the N-terminal end  
                    is synthesized by automated oligonucleotide synthesis.  
30 The gene sequence with the interconnecting peptide is  
                    subcloned immediately downstream from the carbonic  
                    anhydrase gene. The gene sequence with the  
                    intraconnecting peptide is subcloned immediately  
                    downstream from the first copy of the growth releasing  
35 factor gene. The vector is then introduced into a  
                    bacterial host and expression of the recombinant  
                    multicopy fusion protein is induced as described in  
                    Example 1. The recombinant multicopy fusion protein is  
                    purified as described in Example 1.

40                   The recombinant multicopy fusion protein is  
                    then cleaved with hydroxylamine. Hydroxylamine cleaves

at the Asn-Gly recognition sequence in the inter- and intraconnecting peptides to form single copy polypeptides with N-terminal Gly-Pro-Arg peptide and a C-terminal Asn residue.

5           The single copy polypeptide is then reacted with maleic anhydride to protect  $\epsilon$ -amine and hydroxyl groups. The  $\beta$ - and  $\gamma$ -carboxyl groups are protected by formation of o-nitrophenol esters at those groups.

10           The single copy polypeptide is then cleaved with carboxypeptidase to remove the C-terminal Asn residue. The unprotected C-terminal  $\alpha$ -carboxyl group is amidated by the reaction of the protected single copy polypeptide with dicyclohexylcarbodiimide followed by an excess of ammonia.

15           The single copy polypeptide is then cleaved with thrombin to remove the N-terminal biological protecting group-Gly-Pro-Arg. The unprotected N-terminal  $\alpha$ -amine is then reacted with a urethane blocked pyroglutamyl residue to form a protected  
20 N-terminally modified, C-terminally modified single copy polypeptide. The terminally modified single copy polypeptide is deprotected at about pH=2 for 2 hours, followed by deprotection at pH=9 for about 2 hours. The final product is growth releasing factor modified at the  
25 N-terminal with a pyroglutamyl residue and modified at the C-terminal by amidation.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Stout, Jay  
Wagner, Fred W.  
Coolidge, Thomas R.  
Holmquist, Barton
- (ii) TITLE OF INVENTION: METHOD FOR MODIFICATION OF  
RECOMBINANT POLYPEPTIDES
- (iii) NUMBER OF SEQUENCES: 15
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Merchant & Gould
  - (B) STREET: 3100 Norwest Center
  - (C) CITY: Minneapolis
  - (D) STATE: MN
  - (E) COUNTRY: USA
  - (F) ZIP: 55402
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE:  
PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Nelson, Albin J.
  - (B) REGISTRATION NUMBER: 28,650
  - (C) REFERENCE/DOCKET NUMBER: 8648.35-WO-01
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 612-332-5300
  - (B) TELEFAX: 612-332-9081

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 20 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Ala	Phe	Ser	Lys	Ala	Phe	Ser	Lys	Ala	Phe	Ser	Lys	Ala	Phe	Ser	Lys
1				5				10				15			

Ala	Phe	Ser	Lys
			20

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 5 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Asp	Asp	Asp	Asp	Lys
1				5

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 4 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Ile Glu Gly Arg  
1

## (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 4 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Arg Gly Pro Arg  
1

85

## (2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 8 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

His Pro Phe His Leu Leu Val Tyr  
1                    5

## (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 30 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Phe Val Asp Asp Asp Asp Lys Phe Val Asn Gly Pro Arg Ala Met Phe  
1                    5                    10                    15

Val Asp Asp Asp Asp Lys Val Asn Gly Pro Arg Ala Met Ala  
                    20                    25                    30

## (2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 15 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu  
1                    5                    10                    15

## (2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 5 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Val Asp Asp Asp Lys  
1                    5

## (2) INFORMATION FOR SEQ ID NO:9:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Lys Arg Arg Trp Lys Lys Asn Phe Ala Val  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:10:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Gly Asn Gly Phe Ser Pro Phe Arg Gly Phe Ser Pro Phe Arg  
1 5 10 15

Gly Phe Ser Pro Phe Arg  
20

## (2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 4 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Asn Gly Pro Arg  
1

## (2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GACGACGACG ATAAA

89

## (2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 12 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

ATTGAAGGAA GA

12

## (2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 12 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AGAGGACCAA GA

12

## (2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CATCCTTTTC ATCTGCTGGT TTAT

24

## WHAT IS CLAIMED IS:

1. A method for preparing a recombinant single copy polypeptide or a portion thereof with a modified terminal amino acid  $\alpha$ -carbon reactive group selected from the group consisting of N-terminal  $\alpha$ -amine, C-terminal  $\alpha$ -carboxyl and a combination thereof, and reactive side chain groups selected from the group consisting of an  $\epsilon$ -amine group, a hydroxyl group, a  $\beta$ -carboxyl group, a  $\gamma$ -carboxyl group, a thiol group, and a combination thereof, comprising:
  - forming the recombinant single copy polypeptide or a portion thereof so that the single copy polypeptide is protected with one or more biologically added protecting groups on the terminal amino acid  $\alpha$ -carbon reactive group selected from the group consisting of N-terminal  $\alpha$ -amine, C-terminal  $\alpha$ -carboxyl and a combination thereof;
  - conducting the following reacting and cleaving steps in any order to produce a side chain protected single copy polypeptide having at least one unprotected terminal amino acid  $\alpha$ -carbon reactive group;
  - reacting the recombinant single copy polypeptide with up to three chemical protecting agents to selectively protect a reactive side chain group selected from the group consisting of  $\epsilon$ -amine, hydroxyl,  $\beta$ -carboxyl,  $\gamma$ -carboxyl, thiol, and a combination thereof;
  - cleaving the recombinant single copy polypeptide with at least one cleavage reagent specific for the biologically added protecting group to form an unprotected terminal amino acid  $\alpha$ -carbon reactive group;
  - modifying the unprotected terminal amino acid  $\alpha$ -carbon reactive group with at least one chemical modifying agent to form a terminally

modified side chain protected single copy polypeptide; and

5           deprotecting the terminally modified side chain protected single copy polypeptide to form the terminally modified single copy polypeptide.

2. The method according to claim 1, wherein

10           the recombinant single copy polypeptide is formed with a biologically added protecting group at the N-terminal  $\alpha$ -amine reactive side chain group by an amide bond connection to a different polypeptide, the different polypeptide comprising either an interconnecting peptide or a binding protein connected to an interconnecting peptide and the  
15           interconnecting peptide, having at least one site cleavable by a chemical or enzymatic reagent and being the amide bond connection to the recombinant single copy polypeptide, and

20           the cleavage reagent specific for the biologically added protecting group is an enzyme or chemical that cleaves at the interconnecting peptide, and

25           the chemical modifying agent acts to form an acetyl group at the N-terminal  $\alpha$ -amine group.

3. The method according to claim 1, further comprising:

30           forming a recombinant single copy polypeptide so that the single copy polypeptide is protected by a first biologically added protecting group at the N-terminal  $\alpha$ -amine group by an amide bond connected to a different polypeptide, the different polypeptide being either an interconnecting peptide or a binding protein connected to an interconnecting peptide and the  
35           interconnecting peptide being the amide bond connection and the single copy polypeptide is protected by a second biologically added protecting

group at the C-terminal  $\alpha$ -carboxyl group by an amide bond connection to an arginine;

5           cleaving the recombinant single copy polypeptide with the cleavage reagent specific for the first biologically added protecting group to form a side chain protected single copy polypeptide having an unprotected N-terminal  $\alpha$ -amine;

10           modifying the unprotected N-terminal  $\alpha$ -amine with the first chemical modifying agent to form an N-terminal  $\alpha$ -amine modified side chain protected single copy polypeptide;

15           cleaving the N-terminal  $\alpha$ -amine modified side chain protected single copy polypeptide with a second cleavage reagent specific for the second biologically added protecting group to form an N-terminal  $\alpha$ -amine modified side chain protected single copy polypeptide with an unprotected C-terminal  $\alpha$ -carboxyl group; and

20           modifying the unprotected C-terminal  $\alpha$ -carboxyl group with a second modifying agent to form a N-terminal and C-terminal modified side chain protected single copy polypeptide.

4.   25   A method for the preparation of a recombinant single copy polypeptide or a portion thereof with a modified C-terminal  $\alpha$ -carboxyl group, an N-terminal  $\alpha$ -amine group, and reactive side chain groups selected from the group consisting of an  $\epsilon$ -amine group, a hydroxyl group, a  $\beta$ -carboxyl group, a  $\gamma$ -carboxyl group, a thiol group, and a combination thereof, which is obtained from expression and purification of a recombinant single copy fusion protein of three tandem coupled segments, the first segment being a binding protein, the second segment 30   being an interconnecting peptide and the third segment being the single copy polypeptide or a portion thereof, comprising:

35

cleaving the recombinant single copy fusion protein with a cleavage reagent specific for the interconnecting peptide to produce a single copy polypeptide or a portion thereof;

5            reacting the single copy polypeptide or a portion thereof with up to three chemical protecting agents to selectively protect a reactive side chain group selected from the group consisting of  $\epsilon$ -amine, hydroxyl,  $\beta$ -carboxyl,  $\gamma$ -carboxyl, thiol, and a  
10           combination thereof, to form a side chain protected single copy polypeptide with an unprotected C-terminal  $\alpha$ -carboxyl group;

             modifying the C-terminal  $\alpha$ -carboxyl group of the side chain protected single copy polypeptide  
15           with a chemical modifying agent to form a C-terminal  $\alpha$ -carboxyl modified side chain protected single copy polypeptide; and

             deprotecting the C-terminal  $\alpha$ -carboxyl modified side chain protected single copy  
20           polypeptide to form the C-terminal  $\alpha$ -carboxyl modified recombinant single copy polypeptide.

5.    A method for preparing a modified recombinant single copy polypeptide or a portion thereof with a  
25           modified terminal amino acid  $\alpha$ -carbon reactive group selected from the group consisting of N-terminal  $\alpha$ -amine, C-terminal  $\alpha$ -carboxyl and a combination thereof, and reactive side chain groups selected from the group consisting of an  $\epsilon$ -amine group, a  
30           hydroxyl group, a  $\beta$ -carboxyl group, a  $\gamma$ -carboxyl group, and a combination thereof comprising:

             forming the recombinant single copy polypeptide or a portion thereof so that the single copy polypeptide is protected with one or more  
35           biologically added protecting groups on the terminal amino acid  $\alpha$ -carbon reactive group selected from the

group consisting of N-terminal  $\alpha$ -amine, C-terminal  $\alpha$ -carboxyl, and a combination thereof;

5 cleaving the recombinant single copy polypeptide or a portion thereof with at least one cleavage reagent specific for the biologically added protecting group to form a recombinant single copy polypeptide with an unprotected terminal amino acid  $\alpha$ -carbon reactive group; and

10 modifying the unprotected terminal amino acid  $\alpha$ -carbon reactive group with at least one chemical modifying agent to form a terminally modified single copy polypeptide.

6. A method according to claim 1, wherein in the step  
15 of forming a recombinant single copy polypeptide or a portion thereof, a portion of the recombinant single copy polypeptide lacks about 1 to about 10 terminal amino acids.

20 7. The method according to claim 1, wherein the chemical protecting agent is an agent that selectively protects amine and hydroxyl groups selected from the group consisting of alkyl substituted anhydrides, aryl substituted anhydrides,  
25 alkoxy substituted anhydrides, diazo compounds, cyclic anhydrides, alkyl substituted carbamating agents, and aryl substituted carbamating agents.

8. The method of claim 1, wherein in the step of  
30 reacting the single copy polypeptide with up to three protecting agents, the single copy polypeptide is reacted with a protecting agent that selectively protects amine groups and is then reacted with a protecting agent that selectively protects carboxyl  
35 groups.

9. The method according to claim 1, wherein in the step of deprotecting the terminally modified single copy polypeptide comprises incubating the protected single copy polypeptide at a pH about 2-4 until substantially all of the protecting groups are removed.
10. A biologically added protecting group for a recombinant single copy polypeptide comprising: a peptide or amino acid that contains at least one recognition sequence for a cleavage reagent.
11. A biologically added protecting group according to claim 10, wherein the peptide contains more than one cleavage recognition sequence.
12. A biologically added protecting group according to claim 11, wherein the peptide contains an enzymatic cleavage recognition site and a chemical cleavage recognition site.
13. A biologically added protecting group according to claim 10, wherein the recognition sequence is not present in the single copy polypeptide.
14. A method for preparing a recombinant single copy polypeptide or a portion thereof with a modified terminal amino acid  $\alpha$ -carbon reactive group selected from the group consisting of N-terminal  $\alpha$ -amine, C-terminal  $\alpha$ -carboxyl and a combination thereof, and reactive side chain groups selected from the group consisting of an  $\epsilon$ -amine group, a hydroxyl group, a  $\beta$ -carboxyl group, a  $\gamma$ -carboxyl group, a thiol group, and a combination thereof, the recombinant single copy polypeptide being obtained from expression and purification of a recombinant multicopy polypeptide,

the recombinant multicopy polypeptide having multiple copies of the single copy polypeptide connected by an intraconnecting peptide, comprising:

forming the recombinant multicopy

5 polypeptide so that it is protected with one or more biologically added protecting group on a terminal amino acid  $\alpha$ -carbon reactive group selected from the group consisting of N-terminal  $\alpha$ -amine, C-terminal  $\alpha$ -carboxyl, and a combination thereof;

10 conducting the following reacting and cleaving steps in any order to produce a side chain protected single copy polypeptide having at least one unprotected terminal amino acid  $\alpha$ -carbon reactive group;

15 reacting the recombinant single or multicopy polypeptide with up to three chemical protecting agents to selectively protect a reactive side chain group selected from the group consisting of  $\epsilon$ -amine, hydroxyl,  $\beta$ -carboxyl,  $\gamma$ -carboxyl, thiol, and a combination thereof;

20 cleaving the recombinant multicopy polypeptide with at least one cleavage reagent specific for the biologically added protecting group to form an unprotected terminal amino acid  $\alpha$ -carbon reactive group;

25 modifying the unprotected N-terminal  $\alpha$ -amine or C-terminal  $\alpha$ -carboxyl group with a chemical modifying agent to form a modified N-terminal  $\alpha$ -amine or C-terminal  $\alpha$ -carboxyl side chain protected single copy polypeptide; and

30 deprotecting the N-terminal  $\alpha$ -amine modified or C-terminal  $\alpha$ -carboxyl modified side chain protected single copy polypeptide to form a terminally modified single copy polypeptide.

35

15. A method according to claim 14, further comprising reacting the recombinant single copy polypeptide

with up to three chemical protecting agents to form a side chain protected single copy polypeptide with the step of cleaving the recombinant multicopy polypeptide with a cleavage reagent specific for the intraconnecting peptide to form a single copy polypeptide.

16. A method according to claim 15, further comprising:  
forming the recombinant multicopy polypeptide with a biologically added protecting group comprising:  
two tandemly coupled segments, the first segment being a binding protein and the second segment being an interconnecting peptide or a single tandemly coupled segment which is the interconnecting peptide, the interconnecting peptide being connected to the terminal amino  $\alpha$ -carbon reactive group of the multicopy polypeptide; and  
cleaving the recombinant multicopy polypeptide with a cleavage reagent specific for the interconnecting peptide to form a recombinant multicopy polypeptide.

17. A method according to claim 16, further comprising:  
forming the recombinant multicopy polypeptide so that it is protected with an N-terminal biologically added protecting group and a C-terminal biologically added protecting group;  
cleaving the recombinant multicopy polypeptide with a cleavage reagent specific for the N-terminal biologically added protecting group to form a side chain protected single copy polypeptide with an unprotected N-terminal  $\alpha$ -amine reactive group;  
modifying the unprotected N-terminal  $\alpha$ -amine with a first modifying agent to form a

modified N-terminal  $\alpha$ -amine side chain protected single copy polypeptide;

5           cleaving the N-terminal  $\alpha$ -amine modified side chain protected single copy polypeptide with cleavage reagent specific for the C-terminal biologically added protecting group to form a modified N-terminal  $\alpha$ -amine side chain protected single copy with an unprotected C-terminal  $\alpha$ -carbon reactive group; and

10           modifying the C-terminal  $\alpha$ -carbon reactive group to form a modified N-terminal  $\alpha$ -amine, modified C-terminal  $\alpha$ -carboxyl side chain protected single copy polypeptide.

15 18. A method according to claim 17, wherein the N-terminal biologically added protecting group is two segments tandemly coupled together, the first segment being a binding protein, the second segment being an interconnecting peptide or is one segment  
20           which is the interconnecting peptide, and the interconnecting peptide being connected to the N-terminal amino acid of the multicopy polypeptide and the C-terminal biologically added protecting group is arginine.

25 19. A method for preparing a recombinant single copy polypeptide or portion thereof with a modified terminal amino acid  $\alpha$ -carbon selected from the group consisting of N-terminal  $\alpha$ -amine, C-terminal  
30            $\alpha$ -carboxyl and a combination thereof, and reactive side chain group consisting of an  $\epsilon$ -amine group, a hydroxyl group, a  $\beta$ -carboxyl group, a  $\alpha$ -carboxyl group, and a thiol group, and a combination thereof, the recombinant single copy polypeptide or a portion  
35           thereof being obtained from expression and purification of recombinant multicopy polypeptide, the recombinant multicopy polypeptide having

multiple copies of the single copy polypeptide or a portion thereof tandemly linked together, comprising:

- 5 forming the recombinant multicopy polypeptide so that it is protected with one or more biologically added protecting group on a terminal amino acid  $\alpha$ -carbon reactive group selected from the group consisting of N-terminal  $\alpha$ -amine, C-terminal  $\alpha$ -carboxyl and a combination thereof;
- 10 cleaving the recombinant multicopy polypeptide with at least one cleavage reagent that forms single copy polypeptides with an unprotected terminal amino acid  $\alpha$ -carbon reactive group; and
- 15 modifying the unprotected terminal  $\alpha$ -carbon reactive group with a chemical modifying agent to form a terminally modified single copy polypeptide.
20. The method according to claim 19, wherein the  
20 chemical protecting agent is an agent that selectively protects amine and hydroxyl groups selected from the group consisting of alkyl substituted anhydrides, aryl substituted anhydrides, alkoxy substituted anhydrides, diazo compounds,  
25 cyclic anhydrides, alkyl substituted carbamating agents, and aryl substituted carbamating agents.
21. The method of claim 19, wherein in the step of  
30 reacting the single copy polypeptide with up to three protecting agents, the single or multicopy polypeptide is reacted with a protecting agent that selectively protects amine groups and is then reacted with a protecting agent that selectively protects carboxyl groups.
- 35 22. The method of claim 19, wherein the chemical modifying agent is an amidating agent selected from

the group consisting of carbodiimides and ammonia, acid chlorides and ammonia, mixed anhydrides and ammonia, azides and ammonia, o-nitrophenol esters and ammonia, 1-hydroxybenzotriazole esters and ammonia.

23. The method according to claim 19, wherein in the step of deprotecting the terminally modified single copy polypeptide comprises incubating the protected single copy polypeptide at a pH about 2-4 until substantially all of the protecting groups are removed.

24. The method according to claim 2, wherein the interconnecting peptide contains at least two cleavage sites and the cleavage site nearest the binding protein is cleaved to form the biologically added protecting group from the interconnecting peptide residue.

25. A method according to claim 24, wherein the interconnecting peptide contains at least two cleavage sites and the cleavage site nearest the binding protein is cleaved to form the biologically added protecting group from the interconnecting peptide residue.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 5 :</b>  <b>C07K 1/00, 3/08</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 94/01451</b>  <b>(43) International Publication Date:</b> 20 January 1994 (20.01.94)
<b>(21) International Application Number:</b> PCT/US93/06591 <b>(22) International Filing Date:</b> 13 July 1993 (13.07.93)  <b>(30) Priority data:</b> 07/912,798                      13 July 1992 (13.07.92)                      US  <b>(71) Applicant:</b> BIONEBRASKA, INC. [US/US]; 3940 Cornhusker Highway, Suite 600, Lincoln, NE 68504 (US). <b>(72) Inventors:</b> STOUT, Jay ; 1921 Sewell, Lincoln, NE 68502 (US). WAGNER, Fred, W. ; Route 1, Box 77B, Walton, NE 68461 (US). COOLIDGE, Thomas, R. ; Beebe Hill Road, Falls Village, CT 06031 (US). HOLMQUIST, Bart ; 335 Prospect Hill Road, Waltham, CT 02154 (US).		<b>(74) Agent:</b> BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Welter & Schmidt, 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402 (US).  <b>(81) Designated States:</b> AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 3 March 1994 (03.03.94)
<b>(54) Title:</b> METHOD FOR MODIFICATION OF RECOMBINANT POLYPEPTIDES		
<b>(57) Abstract</b>  <p>The invention provides for a chemical method for preparing a recombinant single copy polypeptide or a portion thereof with a modified terminal amino acid <math>\alpha</math>-carbon reactive group selected from the group consisting of N-terminal <math>\alpha</math>-amine, C-terminal <math>\alpha</math>-carboxyl, and a combination thereof. The steps of the method involve forming the recombinant single copy polypeptide or a portion thereof so that the single copy polypeptide is protected with one or more biologically added protecting groups at the N-terminal <math>\alpha</math>-amine, C-terminal <math>\alpha</math>-carboxyl. The recombinant single copy polypeptide can then be reacted with up to three chemical protecting agents to selectively protect reactive side chain groups and thereby prevent side chain groups from being modified. The recombinant single copy polypeptide can be cleaved with at least one cleavage reagent specific for the biological protecting group to form an unprotected terminal amino acid <math>\alpha</math>-carbon reactive group. The unprotected terminal amino acid <math>\alpha</math>-carbon reactive group is modified with at least one chemical modifying agent. The side chain protected terminally modified single copy polypeptide is then deprotected at the side chain groups to form a terminally modified recombinant single copy polypeptide. The number and sequence of steps in the method can be varied to achieve selective modification at the N- and/or C-terminal amino acid of a recombinantly produced polypeptide.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 93/06591

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 C07K1/00 C07K3/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCIENCE vol. 177 , 18 August 1972 , LANCASTER, PA US pages 623 - 626 M.A. RUTTENBERG 'Human Insulin: Facile Synthesis by Modification of Porcine Insulin' see page 623, right column, paragraph 3 - page 624, left column, paragraph 2 ---	1,2,5-10
X	HOPPE-SEYLER'S ZEITSCHRIFT FÜR PHYSIOLOGISCHEN CHEMIE vol. 357 , June 1976 , BERLIN D pages 759 - 767 R. OBERMEIER AND R. GEIGER 'A New Semisynthesis of Human Insulin' see Results and Discussion on pages 763-767 --- -/--	1,2,5-10

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier document but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
"&" document member of the same patent family

Date of the actual completion of the international search

20 December 1993

Date of mailing of the international search report

01-02-1994

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Fuhr, C

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 93/06591

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB,A,2 246 133 (FARMITALIA CARLO ERBA S.R.L.) 22 January 1992 see page 5, last paragraph - page 8, last paragraph; claims ---	1,2,5,6, 10-13
E	FR,A,2 687 680 (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE) 27 August 1993 see claims; examples ---	1
P,X	EP,A,0 511 003 (ELI LILLY AND COMPANY) 28 October 1992 see page 7, line 21 - line 43; claims; examples ---	1,2,5,6, 10-13
X	WO,A,88 02406 (MASSACHUSETTS INSTITUTE OF TECHNOLOGY) 7 April 1988 see page 12, last paragraph - page 13, paragraph 2; claims ---	10-13
A	EP,A,0 197 794 (SANKYO COMPANY LIMITED) 15 October 1986 see claims; examples -----	1

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 93/06591

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A-2246133	22-01-92	DE-A- 4122688 JP-A- 4252185	16-01-92 08-09-92
FR-A-2687680	27-08-93	NONE	
EP-A-0511003	28-10-92	AU-A- 1513292 CN-A- 1068123	29-10-92 20-01-93
WO-A-8802406	07-04-88	EP-A- 0324789 JP-T- 2501618 US-A- 5132213 US-A- 5093242 US-A- 5196321	26-07-89 07-06-90 21-07-92 03-03-92 23-03-93
EP-A-0197794	15-10-86	CA-A- 1251153 JP-A- 62029997 US-A- 4709014	14-03-89 07-02-87 24-11-87